WO2012012694A2 - Methods of detecting autoimmune or immune-related diseases or conditions - Google Patents
Methods of detecting autoimmune or immune-related diseases or conditions Download PDFInfo
- Publication number
- WO2012012694A2 WO2012012694A2 PCT/US2011/044973 US2011044973W WO2012012694A2 WO 2012012694 A2 WO2012012694 A2 WO 2012012694A2 US 2011044973 W US2011044973 W US 2011044973W WO 2012012694 A2 WO2012012694 A2 WO 2012012694A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- profile
- phagocytic cells
- condition
- cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- This invention relates generally to methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of autoimmune or immune-related diseases or conditions.
- the invention also relates to methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of autoimmune or immune-related diseases or conditions.
- Leukocytes begin as pluripotent hematopoietic stem cells in the bone marrow and develop along either the myeloid lineage (monocytes, macrophages, neutrophils, eosinophils, and basophils) or the lymphoid lineage (T and B lymphocytes and natural killer cells).
- the major function of the myeloid lineage cells e.g., neutrophils and macrophages
- the major function of the myeloid lineage cells e.g., neutrophils and macrophages
- Phagocytes from healthy animals do not replicate and are diploid, i.e., have a DNA index of one. On average, each cell contains ⁇ 10 ng DNA, ⁇ 20 ng RNA, and ⁇ 300 ng of protein.
- One object of the present invention is to provide diagnostic methods that can facilitate the detection of autoimmune or immune-related disease or condition- specific markers, e.g., nucleic acids, proteins, carbohydrates, and/or lipids and the like by using phagocytic cells alone, or in combination with non-phagocytic cells.
- Another object of this invention is to provide methods of identifying autoimmune or immune-related disease or condition-specific markers and further use such markers alone or together with any known markers to diagnose diseases or conditions.
- phagocytic cells serve as surrogates for diseased cells and non-phagocytic cells serve as control cells.
- this invention provides a method for diagnosing or aiding in the diagnosis of an autoimmune or immune-related disease or condition in a subject comprising: a) determining a first profile of one or more markers of the disease or condition from a population of phagocytic cells; b) determining a second profile of at least one of the one or more markers from a population of non- phagocytic cells; and c) identifying a difference between the first and second profiles of at least one or more of said markers, wherein the difference is indicative of the presence of said disease or condition in the subject.
- this invention provides a method for assessing the risk of developing an autoimmune or immune-related disease or condition in a subject comprising: a) determining a first profile of one or more markers of the disease or condition from a population of phagocytic cells; b) determining a second profile of at least one of the one or more markers from a population of non-phagocytic cells; and c) identifying a difference between the first and second profiles of at least one or more of said markers, wherein the difference is indicative of the risk of developing said disease or condition in the subject.
- this invention provides a method for prognosing or aiding in the prognosis of an autoimmune or immune-related disease or condition in a subject comprising: a) determining a first profile of one or more markers of the disease or condition from a population of phagocytic cells; b) determining a second profile of at least one of the one or more markers from a population of non- phagocytic cells; and c) identifying a difference between the first and second profiles of at least one or more of said markers, wherein the identified difference is indicative of the prognosis of said disease or condition in the subject.
- this invention provides a method for assessing the efficacy of a treatment for an autoimmune or immune-related disease or condition in a subject comprising: a) determining a first profile of one or more markers of the disease or condition from a population of phagocytic cells from the subject before the treatment; determining a second profile of at least one of the one or more markers from a population of non-phagocytic cells from the subject before the treatment; identifying a first difference between the first and second profiles of at least one or more of said markers; b) determining a third profile of the one or more markers from a population of phagocytic cells from the subject after the treatment; determining a fourth profile of at least one of the one or more markers from a population of non-phagocytic cells from the subject after the treatment; identifying a second difference between the third and fourth profiles of at least one or more of said markers; and c) identifying a difference between the first difference and the second difference, wherein the identified difference
- this invention provides a method for monitoring the progression or regression of an autoimmune or immune-related disease or condition in a subject comprising: a) determining a first profile of one or more markers of the disease or condition from a population of phagocytic cells from the subject at a first time point; determining a second profile of at least one of the one or more markers from a population of non-phagocytic cells from the subject at the first time point; identifying a first difference between the first and second profiles of at least one or more of said markers; b) determining a third profile of the one or more markers from a population of phagocytic cells from the subject at a second time point; determining a fourth profile of at least one of the one or more markers from a population of non-phagocytic cells from the subject at the second time point; identifying a second difference between the third and fourth profiles of at least one or more of said markers; and c) identifying a difference between the first difference and the second difference,
- this invention provides a method for identifying a compound capable of ameliorating or treating an autoimmune or immune-related disease or condition in a subject comprising: a) determining a first profile of one or more markers of the disease or condition from a population of phagocytic cells from the subject before administering the compound to the subject;
- this invention provides a method for identifying one or more markers for an autoimmune or immune-related disease or condition comprising: a) determining a first profile of analytes from phagocytic cells from a subject having said disease or condition; determining a second profile of analytes from non-phagocytic cells from the subject having said disease or condition;
- identifying a first set of differences between the first and second profiles wherein the first set of differences is specific to the first profile relative to the second profile; b) determining a third profile of analytes from phagocytic cells from a control subject not having said disease or condition; determining a fourth profile of analytes from non-phagocytic cells from the control subject not having said disease or condition; identifying a second set of differences between the third and fourth profiles, wherein the second set of differences is specific to the third profile relative to the fourth profile; c) identifying one or more analytes specific to the first set of differences relative to the second set of differences, the identified analytes being markers of said disease or condition.
- this method further comprises d) obtaining a fifth profile of analytes from cells or tissues affected by said disease or condition in the subject having said disease or condition; obtaining a sixth profile of analytes from cells or tissues not affected by said disease or condition in the subject having said disease or condition; identifying a third set of differences between the fifth and sixth profiles, wherein the third set of differences is specific to the fifth profile relative to the sixth profile; and e) identifying at least one of the one or more markers of c) present in the third set of differences.
- this invention provides a method for identifying one or more markers of an autoimmune or immune-related disease or condition comprision: a) determining a first profile of analytes from phagocytic cells from a subject having said disease or condition; determining a second profile of analytes from phagocytic cells from a control subject not having said disease or condition; identifying a first set of differences between the first and second profiles, wherein the first set of differences is specific to the first profile relative to the second profile; b) determining a third profile of analytes from non-phagocytic cells from the subject having said disease or condition; determining a fourth profile of analytes from non-phagocytic cells from the control subject not having said disease or condition; identifying a second set of differences between the third and fourth profiles, wherein the second set of differences is specific to the third profile relative to the fourth profile; c) identifying one or more analytes specific to the first set of differences relative to the second set
- the method further comprises d) obtaining a fifth profile of analytes from cells or tissues affected by said disease or condition in the subject having said disease or condition; obtaining a sixth profile of analytes from cells or tissues not affected by said disease or condition in the subject having said disease or condition; identifying a third set of differences between the fifth and sixth profiles, wherein the third set of differences is specific to the fifth profile relative to the sixth profile; and e) identifying at least one of the one or more markers of c) present in the third set of differences.
- this invention provides a method for identifying one or more markers of an autoimmune or immune-related disease or condition comprising: a) determining a first profile of analytes from phagocytic cells from a subject having said disease or condition; obtaining a second profile of analytes from phagocytic cells from a control subject not having said disease or condition by data mining; identifying a first set of differences between the first and second profiles, wherein the first set of differences is specific to the first profile relative to the second profile; b) determining a third profile of analytes from non-phagocytic cells from the subject having said disease or condition; obtaining a fourth profile of analytes from non-phagocytic cells from a control subject not having said disease or condition by data mining; identifying a second set of differences between the third and fourth profiles, wherein the second set of differences is specific to the third profile relative to the fourth profile; and c) identifying one or more analytes specific to the first set
- the method further comprises d) obtaining a fifth profile of analytes from cells or tissues affected by said disease or condition by data mining; obtaining a sixth profile of analytes from cells or tissues not affected by said disease or condition by data mining; identifying a third set of differences between the fifth and sixth profiles, wherein the third set of differences is specific to the fifth profile relative to the sixth profile; and e) identifying at least one of the one or more markers of c) present in the third set of differences.
- this invention provides a method for identifying one or more markers of an autoimmune or immune-related disease or condition comprising: a) determining a first profile of analytes from phagocytic cells from a subject having said disease or condition; determining a second profile of analytes from non-phagocytic cells from the subject having said disease or condition;
- the method further comprises d) determining a fifth profile of analytes from phagocytic cells from a control subject not having said disease or condition; identifying a third set of differences between the first and fifth profiles, wherein the third set of differences is specific to the first profile relative to the fifth profile; e) identifying at least one of the one or more markers of c) present in the third set of differences.
- the method further comprises: d) obtaining a fifth profile of analytes from cells or tissues affected by said disease or condition from the subject having said disease or condition; obtaining a sixth profile of analytes from cells or tissues not affected by said disease or condition from the subject having said disease or condition;
- the markers or the analytes are nucleic acids (e.g., nucleotides, oligonucleotides, DNAs, RNAs, or DNA-RNA hybrids), proteins (e.g., , amino acids, peptides, enzymes, antigens, antibodies, cytokines, lipoproteins, glycoproteins, or hormones), lipids (e.g., fatty acids, phosphatides, cholesterol), carbohydrates (e.g., monosaccharides, disaccharides,
- polysaccharides polysaccharides
- metabolites e.g., vitamins, primary metabolites, secondary metabolites
- combinations thereof e.g., vitamins, primary metabolites, secondary metabolites
- the profile is a nucleic acid profile (e.g., genotypic profile, a single nucleotide polymorphism profile, a gene mutation profile, a gene copy number profile, a DNA methylation profile, a DNA acetylation profile, a chromosome dosage profile, a gene expression profile), a protein profile (e.g., protein expression, protein activation), a lipid profile, a carbohydrate profile, a metabolite profile, or a combination thereof.
- the profile is determined by a qualitative assay, a quantitative assay, or a combination thereof.
- the first profile, the second profile, the third profile, the fourth profile, the fifth profile, or the sixth profile comprises the absence of at least one of the one or more markers.
- the difference is at least 1.05-fold, 1.1 -fold, 1.2- fold, 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 2.5-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7- fold, 8-fold, 9-fold, or 10-fold difference.
- the cellular contents of the phagocytic cells comprise viable diseased cells, dead diseased cells, apoptotic diseased cells, circulating tumor cells, infectious agents, fetal cells, trophoblasts, or fragments thereof.
- the cellular contents of the >2n phagocytic cells comprise viable diseased cells, dead diseased cells, apoptotic diseased cells, circulating tumor cells, infectious agents, fetal cells, trophoblasts, or fragments thereof.
- the methods of this invention also comprise comparing the identified difference of c) to a repository of one or more known markers of said disease or condition (e.g., data obtained by data mining).
- the phagocytic cells are professional phagocytic cells (e.g., neutrophils, macrophages, monocytes, dendritic cells, foam cells, mast cells, eosinophils), non-professional phagocytic cells (e.g., epithelial cells, endothelial cells, fibroblasts, mesenchymal cells), or mixtures thereof.
- the non-phagocytic cells are T cells, B cells, null cells, basophils, or mixtures thereof.
- the non-phagocytic cells are isolated from a bodily fluid sample (e.g., blood, urine), tissues, or cells (e.g., white blood cells, fetal cells) of the subject.
- non-phagocytic cells from bodily fluids, tissues or cells
- phagocytic cells from non-phagocytic cells
- >2n phagocytic cells from 2n phagocytic cells
- the phagocytic cells can also be isolated by using a product secreted by the phagocytic cells, or by using a cell surface target (e.g., a receptor protein, a marker of said disease or condition) on the surface of the phagocytic cells.
- a cell surface target e.g., a receptor protein, a marker of said disease or condition
- the target is expressed by the phagocytic cells. In other embodiments, the target is not expressed by the phagocytic cells.
- the non-phagocytic cells are isolated using a ligand that binds to a molecular receptor expressed on the plasma membranes of white blood cells.
- markers that can be used in the methods of this invention and that can be identified by the methods of this invention.
- FIG. 1A schematically depicts one embodiment of a method of the invention for diagnosing or aiding in the diagnosis of an autoimmune or immune- related disease or condition.
- phagocytic cells and non- phagocytic cells are separated from white blood cells of a subject.
- the phagocytic cells serve as surrogates for diseased cells, while the non-phagocytic cells serve as control cells.
- FIG. IB schematically depicts one proposed pathway leading to acquisition of an autoimmune or immune-related disease-specific DNA, RNA, protein and/or lipid markers by phagocytic cells.
- Blood phagocytes engulf viable circulating diseased cells, apoptotic diseased cells, and/or fragmented diseased cells.
- the disease-specific markers e.g., DNAs, RNAs, proteins, or lipids
- non-phagocytic cells do not internalize these diseased cells/fragments, and, therefore, do not contain and/or express the disease- specific markers.
- FIG. 1C schematically depicts a general flowchart of one embodiment of a method of the invention.
- FIG. ID schematically depicts a general flowchart of one embodiment of a method of the invention.
- FIG. 2 A schematically depicts one embodiment of a method of this invention for identifying one or more markers of an autoimmune or immune- related disease or condition.
- D represents diseased cells/tissues from a patient having an autoimmune or immune-related disease or condition; and ND represents not-diseased cells/tissues from the patient;
- M D represents macrophages taken from the patient;
- TCD represents T cells taken from the patient(s);
- M C represents macrophages taken from a control subject not having the disease or condition;
- TCc represents T cells taken from the control subject.
- FIG. 2B schematically depicts one embodiment of a method of this invention for identifying one or more markers of an autoimmune or immune- related disease or condition.
- D represents diseased cells/tissues from a patient having an autoimmune or immune-related disease or condition; and ND represents not-diseased cells/tissues from the patient;
- M D represents macrophages taken from the patient;
- TCD represents T cells taken from the patient;
- Mc represents macrophages taken from a control subject not having the disease or condition;
- TCc represents T cells taken from the control subject.
- FIG. 2C schematically depicts one embodiment of a method of this invention for identifying one or more markers of an autoimmune or immune- related disease or condition.
- D represents information obtained by data mining about diseased cells/tissues from patients having an autoimmune or immune- related disease or condition; and ND represents information obtained by data mining about not-diseased cells/tissues from patients having the same disease or condition;
- MD represents macrophages taken from a patient having the disease or condition;
- TCD represents T cells taken from the patient;
- M c represents information obtained by data mining about macrophages from control subjects not having the disease or condition;
- TCc represents information obtained by data mining about T cells obtained from control subjects not having the disease or condition.
- FIG. 3 depicts a schematic of gene expression profile data that could be compared to identify autoimmune or immune-related disease-specific genes selectively acquired/expressed by macrophages.
- FIG. 4A schematically depicts one embodiment of a method of this invention for diagnosing or aiding in the diagnosis of an autoimmune or immune- related disease or condition.
- a blood sample is withdrawn from an individual to be diagnosed.
- the >2n phagocytic cells serve as surrogates for diseased cells and the 2n phagocytic cells serve as control cells.
- FIG. 4B schematically depicts one proposed pathway leading to acquisition of autoimmune or immune-related disease or condition-specific markers (e.g., DNA, RNA, protein and lipid markers) by phagocytic cells.
- Blood phagocytes engulf viable circulating diseased cells, apoptotic diseased cells, and/or fragmented diseased cells.
- the autoimmune or immune-related disease or condition-specific markers e.g., DNAs, RNAs, proteins, or lipids
- phagocytic cells that do not internalize these diseased cells/fragments, and thus, do not contain or express these markers, and remain DNA content of 2n.
- FIG. 5 schematically depicts one embodiment of a method of this invention for identifying one or more markers of an autoimmune or immune- related disease or condition.
- D represents diseased tissues/cells from a patient having an autoimmune or immune-related disease or condition; and ND represents not-diseased tissues/cells from the patient;
- FIG. 6 schematically depicts one embodiment of a method of this invention for identifying autoimmune or immune-related disease or condition- specific markers selectively acquired/expressed by >2n phagocytic cells of a patient.
- FIG. 7 schematically depicts one embodiment of a method of this invention for diagnosing/detecting an autoimmune or immune-related disease or condition by comparing expression profiles obtained from arrays.
- FIG. 8 schematically depicts one embodiment of a method of this invention for identifying one or more markers of an autoimmune or immune- related disease or condition.
- D represents diseased cells/tissues from a patient having an autoimmune or immune-related disease or condition; and ND represents not-diseased cells/tissues from the patient; No represents neutrophils taken from the patient; TCD represents T cells taken from the patient; Nc represents neutrophils obtained from a control subject not having the disease or condition.
- a "patient”, “subject”, or “individual” are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (e.g., bovines, porcines), companion animals (e.g., canines, felines) and rodents (e.g., mice and rats).
- mammals such as humans, primates, livestock animals (e.g., bovines, porcines), companion animals (e.g., canines, felines) and rodents (e.g., mice and rats).
- a control subject refers to any individual that has not been diagnosed as having the disease or condition being assayed.
- the terms "normal control”, “healthy control”, and “not-diseased cells” likewise mean a sample (e.g., cells, serum, tissue) taken from a source (e.g., subject, control subject, cell line) that does not have the condition or disease being assayed and therefore may be used to determine the baseline for the condition or disorder being measured.
- a source e.g., subject, control subject, cell line
- the control subject, normal control, and healthy control include data obtained and used as a standard, i.e. it can be used over and over again for multiple different subjects.
- the data from the control sample could have been obtained in a different set of experiments, for example, it could be an average obtained from a number of healthy subjects and not actually obtained at the time the data for the subject was obtained.
- diagnosis refers to methods by which the skilled artisan can estimate and/or determine whether or not a patient is suffering from a given disease or condition.
- the skilled artisan often makes a diagnosis on the basis of one or more diagnostic indicators, e.g., a marker, the presence, absence, amount, or change in amount of which is indicative of the presence, severity, or absence of the condition.
- prognosis refers to is used herein to refer to the likelihood of an autoimmune or immune-related disease or condition progression, including recurrence of a disease or condition.
- profiles e.g., gene/protein/lipid/carbohydrate expression profiles, genotypes, gene copy number, gene dosage, DNA methylation, etc.
- disease or condition- associated markers e.g., nucleic acids, proteins, lipids, carbohydrates, metabolites
- This invention also provides methods for assessing the risk of developing an autoimmune or immune-related disease or condition, prognosing said disease, monitoring said disease progression or regression, assessing the efficacy of a treatment, or identifying a compound capable of ameliorating or treating said disease or condition.
- Such a subject-specific profile comparison eliminates the dependence on a population-derived average profile for a particular disease or condition, which may introduce error into the detection or diagnosis of a particular disease or condition in the subject.
- the methods of this invention allow detection, diagnosis, and treatment to be personalized to the individual.
- the methods of this invention (i) have high specificity, sensitivity, and accuracy and are capable of detecting disease or condition-specific markers present within a bodily fluid sample, cells or tissues; and (ii) eliminate the "inequality of baseline" that is known to occur among individuals due to intrinsic (e.g., age, gender, ethnic background, health status and the like) and temporal variations in marker expression. Accordingly, in certain aspects, the invention provides noninvasive assays for the early detection of a disease or condition, i.e., before the disease can be diagnosed by conventional diagnostic techniques, e.g., imaging techniques, and, therefore, provide a foundation for improved decision-making relative to the needs and strategies for intervention, prevention, and treatment of individuals with such disease or condition.
- the methods of this invention can be used together with any known diagnostic methods, such as physical inspection, visual inspection, biopsy, scanning, histology, radiology, imaging, ultrasound, use of a commercial kit, genetic testing, immunological testing, analysis of bodily fluids, or monitoring neural activity.
- diagnostic methods such as physical inspection, visual inspection, biopsy, scanning, histology, radiology, imaging, ultrasound, use of a commercial kit, genetic testing, immunological testing, analysis of bodily fluids, or monitoring neural activity.
- Phagocytic cells that can be used in the methods of this invention include all types of cells that are capable of ingesting various types of substances (e.g., apoptotic cells, infectious agents, dead cells, viable cells, cell-free DNAs, cell-free RNAs, cell-free proteins).
- the phagocytic cells are professional phagocytic cells, such as neutrophils, macrophages, monocytes, dendritic cells, foam cells, mast cells, or eosinophils.
- the phagocytic cells are non-professional phagocytic cells, such as epithelial cells, endothelial cells, fibroblasts, or mesenchymal cells.
- the phagocytic cells can be a mixture of different types of phagocytic cells.
- Non- phagocytic cells that can be used in this invention include, but are not limited to, T cells, B cells, null cells, basophils, or mixtures thereof.
- the >2n phagocytic cells refer to phagocytic cells that have a DNA content of greater than 2n
- the 2n phagocytic cells
- phagocytic cells refer to phagocytic cells that have a DNA content of 2n.
- some phagocytic cells engulf live/dying/dead diseased cells (and subcellular fragments thereof) and/or cell-free disease-specific nucleic acids, proteins, carbohydrates and/or lipids present in bodily fluids.
- Such phagocytosis leads to the internalization of these disease markers into the phagocytic cell and, therefore, the DNA content of these phagocytic cells will become greater than 2n.
- some phagocytic cells have not engulfed living/dying/dead diseased cells or fragments and/or cell-free disease-specific nucleic acids, proteins, lipids, and/or carbohydrates present in bodily fluids.
- the DNA contents of this group of phagocytic cells remain 2n.
- the disease-specific markers e.g., DNA with disease-specific mutations
- the mutated DNA of diseased cells is integrated into the normal DNA of the >2n phagocytic cells.
- the internalized disease-specific markers are not expressed by the >2n phagocytic cells.
- the markers may be translocated onto the membranes of the >2n phagocytic cells, or secreted out by the >2n phagocytic cells.
- a "profile" of a marker of a disease or condition can broadly refer to any information concerning the marker. This information can be either qualitative (e.g., presence or absence) or quantitative (e.g., levels, copy numbers, or dosages). In some embodiments, a profile of a marker can indicate the absence of this marker.
- the profile can be a nucleic acid (e.g., DNA or RNA) profile, a protein profile, a lipid profile, a carbohydrate profile, a metabolite profile, or a combination thereof.
- a “marker” as used herein generally refers to an analyte which is differentially detectable in phagocytes and is indicative of the presence of a disease or condition.
- autoimmune or immune-related diseases or conditions can refer to any disease, disorder, or condition affecting or associated with the immune system. Examples of autoimmune or immune-related diseases or conditions include, but are not limited to,
- spondyloarthropathy psoriasis, psoriatic arthritis, myositis, scleroderma, dermatomyositis, autoimmune vasculitis, mixed connective tissue disease, idiopathic thrombocytopenic purpura, Crohn's disease, human adjuvant disease, osteoarthritis, juvenile chronic arthritis, a spondyloarthropathy, an idiopathic inflammatory myopathy, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, thyroiditis, immune-mediated renal disease, a demyelinating disease of the central or peripheral nervous system, idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome, a chronic inflammatory demyelinating polyneuropathy, a hepatobiliary disease, infectious or autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous he
- AIHA pernicious anemia
- pure red cell aplasia PRCA
- Factor VIII deficiency hemophilia A
- autoimmune neutropenia pancytopenia
- leukopenia diseases involving leukocyte diapedesis
- central nervous system CNS
- inflammatory disorders multiple organ injury syndrome, mysathenia gravis, antigen-antibody complex mediated diseases, anti-glomerular basement membrane disease, anti- phospholipid antibody syndrome, allergic neuritis, Bechet disease, Castleman's syndrome, Goodpasture's syndrome, Lambert-Eaton Myasthenic Syndrome, Reynaud's syndrome, Sjorgen's syndrome, Stevens -Johns on syndrome, pemphigoid bullous, pemphigus, autoimmune polyendocrinopathies, Reiter's disease, stiff-man syndrome, giant cell arteritis, immune complex nephritis, IgA nephropathy, IgM polyneuropathies or IgM mediated neuro
- glomerulonephritis primary biliary cirrhosis, Celiac sprue (gluten enteropathy), cryoglobulinemia, and amyotrophic lateral sclerosis (ALS).
- ALS amyotrophic lateral sclerosis
- the methods of this invention can also be applied to the autoimmune or immune-related diseases or conditions disclosed in, for example, United States Patent Application Publications 20070141625, 20090226440, 20090263474, 20100075891, 20100104579, 20100105086, 20100131286, 20100144055, 20100151471, 20090176217, 20090202469, 200201191 18, 20080213280, 20090023166, 20080221016, 20080194474, 20070224638, 20070135335, 20070128189, 20070122413, 20090130683, 200901 10667, and 20090023166, and International Patent Application Publications WO/2009/043848,
- treating refers to taking steps to obtain beneficial or desired results, including clinical results.
- beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms associated with autoimmune or immune-related diseases or conditions.
- administering or "administration of a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art.
- a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitonealy, intravenously, subcutaneous ly, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorbtion, e.g., through a skin duct).
- a compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow, or controlled release of the compound or agent.
- Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
- the administration includes both direct administration, including self-administration, and indirect administration, including the act of prescribing a drug.
- a physician who instructs a patient to self-administer a drug, or to have the drug administered by another and/or who provides a patient with a prescription for a drug is
- a compound or an agent is administered orally, e.g., to a subject by ingestion, or intravenously, e.g., to a subject by injection.
- the orally administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.
- up-regulation or up-regulated can refer to an increase in expression levels (e.g., gene expression or protein expression), gene copy numbers, gene dosages, and other qualitative or quantitative detectable state of the markers.
- down-regulation or down-regulated can refer to an increase in expression levels, gene copy numbers, gene dosages, and other qualitative or quantitative detectable state of the markers.
- activation or activated can refer to an active state of the marker, e.g., a phosphorylation state, a DNA methylation state, or a DNA acetylation state.
- inhibitor or inhibited can refer to a repressed state or an inactivated state of the marker, e.g., a de-phosphorylation state, a ubiquitination state, a DNA de-methylation state.
- methods of this invention also comprise at least one of the following steps before determination of various profiles: i) lysing the phagocytic cells and the non-phagocytic cells; ii) extracting cellular contents from the lysed phagocytic cells, the lysed non-phagocytic cells. Any known cell lysis and extraction methods can be used herein.
- the cellular contents of the phagocytic cells comprise various types of materials that they have engulfed, such as, viable diseased cells, dead diseased cells, apoptotic diseased cells, circulating tumor cells, infectious agents, fetal cells, trophoblasts, or fragments thereof.
- the cellular contents of the >2n phagocytic cells comprise various types of materials that they have engulfed, such as, viable diseased cells, dead diseased cells, apoptotic diseased cells, circulating tumor cells, infectious agents, fetal cells, trophoblasts, or fragments thereof.
- at least one or more markers of an autoimmune or immune-related disease or condition are present in the cellular contents of the >2n phagocytic cells.
- there is no marker present in the cellular contents of the 2n phagocytic cells.
- methods of this invention further comprise comparing the identified difference of the disease or condition-specific markers to a repository of at least one markers known in the art. Such comparison can further confirm the presence of the disease or condition.
- the repository of the known markers can be obtained by data mining.
- data mining refers to a process of finding new data patterns, relations, or correlations derived from the known data of the databases and of extracting practicable information in the future.
- a computer-based system can be trained on data to perform the data mining, e.g., to classify the input data and then subsequently used with new input data to make decisions based on the training data.
- systems include, but are not limited, expert systems, fuzzy logic, nonlinear regression analysis, multivariate analysis, decision tree classifiers, and Bayesian belief networks.
- the non-phagocytic cells are isolated from a bodily fluid sample, tissues, or cells.
- Exemplar bodily fluid sample can be whole blood, urine, stool, saliva, lymph fluid, cerebrospinal fluid, synovial fluid, cystic fluid, ascites, pleural effusion, fluid obtained from a pregnant woman in the first trimester, fluid obtained from a pregnant woman in the second trimester, fluid obtained from a pregnant woman in the third trimester, maternal blood, amniotic fluid, chorionic villus sample, fluid from a preimplantation embryo, maternal urine, maternal saliva, placental sample, fetal blood, lavage and cervical vaginal fluid, interstitial fluid, or ocular fluid.
- the non-phagocytic cells are isolated from white blood cells.
- cell separation/isolation/purification methods are used to isolate populations of cells from bodily fluid sample, cells, or tissues of a subject. A skilled worker can use any known cell
- Exemplar techniques include, but are not limited to, using antibodies, flow cytometry, fluorescence activated cell sorting, filtration, gradient-based centrifugation, elution, microfluidics, magnetic separation technique, fluorescent- magnetic separation technique, nanostructure, quantum dots, high throughput microscope-based platform, or a combination thereof.
- the phagocytic cells and the non-phagocytic cells are isolated by using a product secreted by the phagocytic cells.
- the phagocytic cells and the non-phagocytic cells are isolated by using a cell surface target (e.g., receptor protein) on the surface of phagocytic cells.
- the cell surface target is a protein that has been engulfed by the phagocytic cells.
- the cell surface target is expressed by the phagocytic cells on their plasma membranes.
- the cell surface target is an exogenous protein that is translocated on the plasma membranes, but not expressed by the phagocytic cells.
- the cell surface target is a marker of the disease or condition to be detected.
- the cell surface target is a protein that has been engulfed by the >2n phagocytic cells.
- the cell surface target is expressed by the >2n phagocytic cells on their plasma membranes.
- the cell surface target is an exogenous protein that is translocated on the plasma membranes, but not expressed by the >2n phagocytic cells. In some embodiments, the cell surface target is a marker of the disease or condition to be detected.
- analytes include nucleic acids, proteins, lipids, carbohydrates, metabolites, or any combinations of these.
- markers include nucleic acids, proteins, lipids, carbohydrates, metabolites, or any combinations of these.
- nucleic acid is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), DNA-RNA hybrids, and analogs of the DNA or RNA generated using nucleotide analogs.
- the nucleic acid molecule can be a nucleotide, oligonucleotide, double-stranded DNA, single- stranded DNA, multi-stranded DNA, complementary DNA, genomic DNA, non- coding DNA, messenger RNA (mRNAs), microRNA (miRNAs), small nucleolar RNA (snoRNAs), ribosomal RNA (rRNA), transfer RNA (tRNA), small interfering RNA (siRNA), heterogeneous nuclear RNAs (hnRNA), or small hairpin RNA (shRNA).
- mRNAs messenger RNA
- miRNAs microRNA
- rRNA ribosomal RNA
- tRNA transfer RNA
- siRNA small interfering RNA
- hnRNA heterogeneous nuclear RNAs
- shRNA small hairpin RNA
- amino acid includes organic compounds containing both a basic amino group and an acidic carboxyl group. Included within this term are natural amino acids (e.g., L-amino acids), modified and unusual amino acids (e.g., D-amino acids and ⁇ -amino acids), as well as amino acids which are known to occur biologically in free or combined form but usually do not occur in proteins.
- natural amino acids e.g., L-amino acids
- modified and unusual amino acids e.g., D-amino acids and ⁇ -amino acids
- Natural protein occurring amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tyrosine, tryptophan, proline, and valine.
- Natural non-protein amino acids include arginosuccinic acid, citrulline, cysteine sulfuric acid, 3,4-dihydroxyphenylalanine, homocysteine, homoserine, ornithine, 3-monoiodotyrosine, 3,5-diiodotryosine, 3, 5, 5 -triiodothyronine, and 3,3',5,5'- tetraiodothyronine.
- Modified or unusual amino acids include D-amino acids, hydroxylysine, 4-hydroxyproline, N-Cbz-protected amino acids, 2,4-diaminobutyric acid, homoarginine, norleucine, N- methylaminobutyric acid, naphthylalanine, phenylglycine, . alpha.
- peptide includes compounds that consist of two or more amino acids that are linked by means of a peptide bond. Peptides may have a molecular weight of less than 10,000 Daltons, less than 5,000 Daltons, or less than 2,500 Daltons. The term “peptide” also includes compounds containing both peptide and non-peptide components, such as pseudopeptide or
- peptidomimetic residues or other non-amino acid components Such compounds containing both peptide and non-peptide components may also be referred to as a "peptide analog.”
- protein includes compounds that consist of amino acids arranged in a linear chain and joined together by peptide bonds between the carboxyl and amino groups of adjacent amino acid residues. Proteins used in methods of the invention include, but are not limited to, amino acids, peptides, antibodies, antibody fragments, cytokines, lipoproteins, or glycoproteins.
- antibody includes polyclonal antibodies, monoclonal antibodies (including full length antibodies which have an
- immunoglobulin Fc region immunoglobulin Fc region
- multispecific antibodies e.g., bispecific antibodies, diabodies, and single-chain molecules
- antibody fragments e.g., Fab or F(ab')2, and Fv.
- Fab or F(ab')2, and Fv antibody fragments
- cytokine refers to a secreted protein or active fragment or mutant thereof that modulates the activity of cells of the immune system.
- cytokines include, without limitation, interleukins, interferons, chemokines, tumor necrosis factors, colony-stimulating factors for immune cell precursors, and the like.
- lipoprotein includes negatively charged compositions that comprise a core of hydrophobic cholesteryl esters and triglyceride surrounded by a surface layer of amphipathic phospholipids with which free cholesterol and apolipoproteins are associated.
- Lipoproteins may be characterized by their density (e.g. very-low-density lipoprotein (VLDL), low- density lipoprotein (LDL) and high density lipoprotein (HDL)), which is determined by their size, the relative amounts of lipid and protein.
- VLDL very-low-density lipoprotein
- LDL low- density lipoprotein
- HDL high density lipoprotein
- Lipoproteins may also be characterized by the presence or absence of particular modifications (e.g. oxidization, acetylation, or glycation).
- glycoprotein includes glycosides which have one or more oligo- or polysaccharides covalently attached to a peptide or protein.
- exemplary glycoproteins can include, without limitation, immunoglobulins, members of the major histocompatibility complex, collagens, mucins, glycoprotein Ilb/IIIa, glycoprotein-41 (gp41) and glycoprotein- 120 (gpl2), follicle-stimulating hormone, alpha- fetoprotein, erythropoietin, transferrins, alkaline phosphatase, and lectins.
- lipid includes synthetic or naturally-occurring compounds which are generally amphipathic and biocompatible. Lipids typically comprise a hydrophilic component and a hydrophobic component. Exemplary lipids include, but are not limited to fatty acids, neutral fats, phosphatides, cholesterol, cholesterol esters, triglycerides, glycolipids, glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids, polyketides, choline glycerophospholipid, ethanolamine glycerophospholipid, phosphatidylinositol, phosphatidylglycerol, phosphatidylserine, lyso-choline glycerophospholipid, lyso-ethanolamine glycerophospholipid, phosphatidic acid, lyso-phosphatidic acid, sphingomyelin, galact
- carbohydrate includes, but is not limited to, compounds that contain oxygen, hydrogen and carbon atoms, typically (CH 2 0) n wherein n is an integer.
- Exemplary carbohydrates include, but are not limited to, monosaccharides, disaccharides, polysaccharides, or oligosaccharides.
- Metabolites includes any molecule used in metabolism. Metabolites can be products, substrates, or intermediates in metabolic processes. Included within this term are primary metabolites, secondary metabolites, organic metabolites, or inorganic metabolites. Metabolites include, without limitation, amino acids, peptides, acylcarnitines, monosaccharides, lipids and phospholipids, prostaglandins, hydroxyeicosatetraenoic acids,
- exemplary metabolites can be sphingolipids, glycosphingolipids, sphingosine, ceramide, sphingomyelin, sphingosylphosphorylcholin,
- dihydrosphingosine phoshatidylcholine, phosphatidylinositol, phosphatidylserine, lysophoshatidylcholine, lysophosphatidylinositol, lysophosphatidylserine, plasmenylphoshatidylcholine, plasmanylphoshatidylcholine, proteinogenic amino acids, Alanine, Aspartic acid, Glutamic acid, Phenylalanine, Glycine, Histidine, Leucine, Isoleucine, Lysine, Methionine, Proline, Arginine, Serine, Threonine, Valine, Tryptophan, Tyrosine, asymmetrical dimethyl arginine, symmetrical dimethyl arginine, Glutamine, Asparagine, Nitrotyrosine, Hydroxyproline, Kynurenine, 3 -Hydroxy kynurenine,
- hydroxylacylcarnitine dicarboxylacylcarnitines, reducing monosaccharides, hexose, pentose, deoxyhexose, creatinine, creatine, spermidine spermine, putrescine, dopamine, serotonin, prostaglandins, hydoxyeicosatetraeneoic acid, Hydroxyoctadecadienoic acid, leukatrienes, thromboxanes, bile acids, sterols, cholesterols, vitamins and cofactors, drugs, and drug metabolites.
- profiles of at least one or more markers of an autoimmune or immune-related disease or condition are compared.
- Quantitative measurements can be taken using any of the assays described herein. For example, sequencing, direct sequencing, random shotgun sequencing, Sanger dideoxy termination sequencing, whole-genome sequencing, sequencing by hybridization, pyrosequencing, capillary electrophoresis, gel electrophoresis, duplex sequencing, cycle sequencing, single- base extension sequencing, solid-phase sequencing, high-throughput sequencing, massively parallel signature sequencing, emulsion PCR, sequencing by reversible dye terminator, paired-end sequencing, near-term sequencing, exonuclease sequencing, sequencing by ligation, short-read sequencing, single-molecule sequencing, sequencing-by-synthesis, real-time sequencing, reverse-terminator sequencing, nanopore sequencing, 454 sequencing, Solexa Genome Analyzer sequencing, SOLiD® sequencing, MS-PET sequencing, mass spectrometry, matrix assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry, electrospray ionization (ES)
- Quantitative comparisons can include statistical analyses such as t-test, ANOVA, Krustal-Wallis, Wilcoxon, Mann- Whitney, and odds ratio.
- Quantitative differences can include differences in the levels of markers between profiles or differences in the numbers of markers present between profiles, and combinations thereof. Examples of levels of the markers can be, without limitation, gene expression levels, nucleic acid levels, protein levels, lipid levels, and the like.
- Qualitative differences can include, but are not limited to, activation and inactivation, protein degradation, nucleic acid degradation, and covalent modifications.
- the profile is a nucleic acid profile, a protein profile, a lipid profile, a carbohydrate profile, a metabolite profile, or a combination thereof.
- the profile can be qualitatively or quantitatively determined.
- a nucleic acid profile can be, without limitation, a genotypic profile, a single nucleotide polymorphism profile, a gene mutation profile, a gene copy number profile, a DNA methylation profile, a DNA acetylation profile, a chromosome dosage profile, a gene expression profile, or a combination thereof.
- the nucleic acid profile can be determined by any methods known in the art to detect genotypes, single nucleotide polymorphisms, gene mutations, gene copy numbers, DNA methylation states, DNA acetylation states, chromosome dosages.
- Exemplar methods include, but are not limited to, polymerase chain reaction (PCR) analysis, sequencing analysis, electrophoretic analysis, restriction fragment length polymorphism (RFLP) analysis, Northern blot analysis, quantitative PCR, reverse-transcriptase-PCR analysis (RT-PCR), allele-specific oligonucleotide hybridization analysis, comparative genomic hybridization, heteroduplex mobility assay (HMA), single strand conformational polymorphism (SSCP), denaturing gradient gel electrophisis (DGGE), RNAase mismatch analysis, mass spectrometry, tandem mass spectrometry, matrix assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry, electrospray ionization (ESI) mass spectrometry, surface-enhanced laser deorption/ionization-time of flight (SELDI-TOF) mass spectrometry, quadrupole- time of flight (Q-TOF) mass spectrometry, atmospheric pressure photoionization mass spect
- HELP Ligation-mediated PCR
- sequencing is used in a broad sense and refers to any technique known in the art that allows the order of at least some consecutive nucleotides in at least part of a nucleic acid to be identified, including without limitation at least part of an extension product or a vector insert.
- Exemplar sequencing techniques include direct sequencing, random shotgun sequencing, Sanger dideoxy termination sequencing, whole-genome sequencing, sequencing by hybridization, pyrosequencing, capillary electrophoresis, gel electrophoresis, duplex sequencing, cycle sequencing, single-base extension sequencing, solid- phase sequencing, high-throughput sequencing, massively parallel signature sequencing, emulsion PCR, sequencing by reversible dye terminator, paired-end sequencing, near-term sequencing, exonuclease sequencing, sequencing by ligation, short-read sequencing, single-molecule sequencing, sequencing-by- synthesis, real-time sequencing, reverse-terminator sequencing, nanopore sequencing, 454 sequencing, Solexa Genome Analyzer sequencing, SOLiD® sequencing, MS-PET sequencing, mass spectrometry, and a combination thereof.
- sequencing comprises an detecting the sequencing product using an instrument, for example but not limited to an ABI PRISM® 377 DNA Sequencer, an ABI PRISM® 310, 3100, 3100-Avant, 3730, or 3730x1 Genetic Analyzer, an ABI PRISM® 3700 DNA Analyzer, or an Applied Biosystems
- an instrument for example but not limited to an ABI PRISM® 377 DNA Sequencer, an ABI PRISM® 310, 3100, 3100-Avant, 3730, or 3730x1 Genetic Analyzer, an ABI PRISM® 3700 DNA Analyzer, or an Applied Biosystems
- sequencing comprises emulsion PCR.
- sequencing comprises a high throughput sequencing technique, for example but not limited to, massively parallel signature sequencing (MPSS).
- MPSS massively parallel signature sequencing
- a protein profile can be a protein expression profile, a protein activation profile, or a combination thereof.
- a protein activation profile can comprise determining a
- phosphorylation state an ubiquitination state, a myristoylation state, or a conformational state of the protein.
- a protein profile can be detected by any methods known in the art for detecting protein expression levels, protein phosphorylation state, protein ubiquitination state, protein myristoylation state, or protein conformational state. In some embodiments, a protein profile can be determined by an
- immunohistochemistry assay an enzyme-linked immunosorbent assay (ELISA), in situ hybridization, chromatography, liquid chromatography, size exclusion chromatography, high performance liquid chromatography (HPLC), gas chromatography, mass spectrometry, tandem mass spectrometry, matrix assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry, electrospray ionization (ESI) mass spectrometry, surface-enhanced laser deorption/ionization-time of flight (SELDI-TOF) mass spectrometry, quadrupole- time of flight (Q-TOF) mass spectrometry, atmospheric pressure photoionization mass spectrometry (APPI-MS), Fourier transform mass spectrometry (FTMS), matrix-assisted laser desorption/ionization-Fourier transform-ion cyclotron resonance (MALDI-FT-ICR) mass spectrometry, secondary ion mass spectrometry (SIMS), radioimmun
- a lipid profile can be determined by chromatography, liquid chromatography, size exclusion chromatography, high performance liquid chromatography (HPLC), gas chromatography, mass spectrometry, tandem mass spectrometry, matrix assisted laser
- MALDI-TOF desorption/ionization-time of flight
- ESI electrospray ionization
- SELDI-TOF surface-enhanced laser deorption/ionization-time of flight
- Q-TOF quadrupole- time of flight
- APPI-MS atmospheric pressure photoionization mass spectrometry
- FTMS Fourier transform mass spectrometry
- MALDI-FT-ICR matrix-assisted laser desorption/ionization-Fourier transform-ion cyclotron resonance
- SIMS secondary ion mass spectrometry
- radioimmunoassays microfluidic chip-based assay, detection of fluorescence, detection of chemiluminescence, or a combination thereof.
- lipid analysis is to extract lipids from a biological sample (e.g.
- fatty acid methyl esters e.g., using 14% BF3 -methanol reagent
- quantify the fatty acid methyl esters e.g., by HPLC, TLC, by gas chromatography-mass spectroscopy using commercially available gas chromatographs, mass
- Fatty acid mass is determined by comparing areas of various analyzed fatty acids to that of a fixed concentration of internal standard.
- a carbohydrate profile can be determined by chromatography, liquid chromatography, size exclusion
- a metabolite profile can be determind by chromatography, liquid chromatography, size exclusion
- the "difference" between different profiles detected by the methods of this invention can refer to different gene copy numbers, different DNA, RNA, protein, lipid, or carbohydrate expression levels, different DNA methylation states, different DNA acetylation states, and different protein modification states.
- the difference can be a difference greater than 1 fold.
- the difference is a 1.05-fold, 1.1 -fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 2.5- fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold difference.
- the difference is any fold difference between 1-10, 2-10, 5-10, 10-20, or 10-100 folds.
- a general principle of assays to detect markers involves preparing a sample or reaction mixture that may contain the marker (e.g., one or more of DNA, RNA, protein, polypeptide, carbohydrate, lipid, metabolite, and the like) and a probe under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture.
- the marker e.g., one or more of DNA, RNA, protein, polypeptide, carbohydrate, lipid, metabolite, and the like
- a probe under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture.
- These assays can be conducted in a variety of ways.
- one method to conduct such an assay would involve anchoring the marker or probe onto a solid phase support, also referred to as a substrate, and detecting target marker/probe complexes anchored on
- a sample from a subject which is to be assayed for presence and/or concentration of marker, can be anchored onto a carrier or solid phase support.
- the reverse situation is possible, in which the probe can be anchored to a solid phase and a sample from a subject can be allowed to react as an unanchored component of the assay.
- anchoring assay components to a solid phase include, without limitation, marker or probe molecules which are immobilized through conjugation of biotin and streptavidin.
- biotinylated assay components can be prepared from biotin-NHS(N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
- biotinylation kit Pierce Chemicals, Rockford, IL
- immobilized assay components can be prepared in advance and stored.
- Suitable carriers or solid phase supports for such assays include any material capable of binding the class of molecule to which the marker or probe belongs.
- Well known supports or carriers include, but are not limited to, glass, polystyrene, nylon, polypropylene, nylon, polyethylene, dextran, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.
- the non- immobilized component is added to the solid phase upon which the second component is anchored.
- uncomplexed components may be removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized upon the solid phase.
- the detection of marker/probe complexes anchored to the solid phase can be accomplished in a number of methods outlined herein.
- the probe when it is the unanchored assay component, can be labeled for the purpose of detection and readout of the assay, either directly or indirectly, with detectable labels discussed herein and which are well-known to one skilled in the art.
- marker/probe complex formation without further manipulation or labeling of either component (marker or probe), for example by utilizing the technique of fluorescence energy transfer (see, for example, U.S. Patent Nos. 5,631,169 and 4,868, 103).
- a fluorophore label on the first, 'donor' molecule is selected such that, upon excitation with incident light of appropriate wavelength, its emitted fluorescent energy will be absorbed by a fluorescent label on a second 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy.
- the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues.
- Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal.
- An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).
- determination of the ability of a probe to recognize a marker can be accomplished without labeling either assay component (probe or marker) by utilizing a technology such as real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C, 1991, Anal. Chem. 63:2338 2345 and Szabo et al, 1995, Curr. Opin. Struct. Biol. 5:699 705).
- BIA or "surface plasmon resonance” is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore).
- analogous diagnostic and prognostic assays can be conducted with marker and probe as solutes in a liquid phase.
- the complexed marker and probe are separated from uncomplexed components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation.
- differential centrifugation marker/probe complexes may be separated from uncomplexed assay components through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas and Minton (1993) Trends Biochem. Sci. 18:284).
- Standard chromatographic techniques may also be utilized to separate complexed molecules from uncomplexed ones.
- gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex may be separated from the relatively smaller uncomplexed components.
- the relatively different charge properties of the marker/probe complex as compared to the uncomplexed components may be exploited to differentiate the complex from uncomplexed components, for example through the utilization of ion-exchange chromatography resins.
- Such resins and chromatographic techniques are well known to one skilled in the art (see, e.g., Heegaard (1998) J. Mol. Recognit. 11 : 141 ; Hage and Tweed (1997) J.
- Gel electrophoresis may also be employed to separate complexed assay components from unbound components (see, e.g., Ausubel et al, ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1987 1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In order to maintain the binding interaction during the electrophoretic process, non-denaturing gel matrix materials and conditions in the absence of reducing agent are typically preferred. Appropriate conditions to the particular assay and components thereof will be well known to one skilled in the art.
- the level of mRNA corresponding to the marker can be determined either by in situ and/or by in vitro formats in a biological sample using methods known in the art. Many expression detection methods use isolated RNA. For in vitro methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from blood cells (see, e.g., Ausubel et al, ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York 1987 1999). Additionally, large numbers of cells and/or samples can readily be processed using techniques well known to those of skill in the art, such as, for example, the single- step RNA isolation process of Chomczynski (1989, U.S. Patent No. 4,843,155).
- Isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays.
- a diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected.
- the nucleic acid probe can be, for example, a full-length cDNA, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to an mRNA or genomic DNA encoding a marker of the present invention.
- Other suitable probes for use in the diagnostic assays of the invention are described herein. Hybridization of an mRNA with the probe indicates that the marker in question is being expressed.
- the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose.
- the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in a gene chip array.
- a skilled artisan can readily adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the markers of the present invention.
- An alternative method for determining the level of mRNA corresponding to a marker of the present invention in a sample involves the process of nucleic acid amplification, e.g., by RT-PCR (the experimental embodiment set forth in U.S. Patent Nos. 4,683, 195 and 4,683,202), COLD-PCR (Li et al. (2008) Nat. Med. 14:579), ligase chain reaction (Barany, 1991, Proc. Natl. Acad. Sci. USA, 88: 189), self sustained sequence replication (Guatelli et al, 1990, Proc. Natl. Acad. Sci. USA 87: 1874), transcriptional amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86: 1 173), Q- Beta Replicase (Lizardi et al. (1988) Bio/Technology 6: 1 197), rolling circle replication (U.S. Patent No.
- amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5 Or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between.
- amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.
- mRNA does not need to be isolated from the sample (e.g., a bodily fluid (e.g., blood cells)) prior to detection.
- a cell or tissue sample is prepared/processed using known histological methods. The sample is then immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the marker.
- determinations may be based on the normalized expression level of the marker.
- Expression levels are normalized by correcting the absolute expression level of a marker by comparing its expression to the expression of a gene that is not a marker, e.g., a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin gene, or epithelial cell- specific genes. This normalization allows the comparison of the expression level in a patient sample from one source to a patient sample from another source, e.g., to compare a phagocytic blood cell from an individual to a non-phagocytic blood cell from the individual.
- a protein or polypeptide corresponding to a marker is detected.
- an agent for detecting a protein or polypeptide can be an antibody capable of binding to the polypeptide, such as an antibody with a detectable label.
- labeled with regard to a probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled.
- Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
- Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof (e.g. , Fab or F(ab')2) can be used. In one format, antibodies, or antibody fragments, can be used in methods such as Western blots or immunofluorescence techniques to detect the expressed proteins. In such uses, it is generally preferable to immobilize either the antibody or proteins on a solid support.
- Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody.
- Well known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, magnetite and the like.
- a variety of formats can be employed to determine whether a sample contains a protein that binds to a given antibody.
- formats include, but are not limited to, competitive and non-competitive immunoassay, enzyme immunoassay (EIA), radioimmunoassay (RIA), antigen capture assays, two-antibody sandwich assays, Western blot analysis, enzyme linked
- Immunoabsorbant assay ELISA
- a planar array a colorimetric assay, a chemiluminescent assay, a fluorescent assay, and the like.
- Immunoassays including radioimmmunoassays and enzyme- linked immunoassays, are useful in the methods of the present invention.
- a skilled artisan can readily adapt known protein/antibody detection methods for use in determining whether cells (e.g., bodily fluid cells such as blood cells) express a marker of the present invention.
- protein isolated from cells e.g., bodily fluid cells such as blood cells
- a solid phase support such as nitrocellulose
- the support can then be washed with suitable buffers followed by treatment with the detectably labeled antibody.
- the solid phase support can then be washed with the buffer a second time to remove unbound antibody.
- the amount of bound label on the solid support can then be detected by conventional means.
- assays are provided for diagnosis, prognosis, assessing the risk of developing a disease, assessing the efficacy of a treatment, monitoring the progression or regression of a disease, and identifying a compound capable of ameliorating or treating a disease.
- An exemplary method for these methods involves obtaining a bodily fluid sample from a test subject and contacting the bodily fluid sample with a compound or an agent capable of detecting one or more of the markers of the disease or condition, e.g., marker nucleic acid (e.g., mRNA, genomic DNA), marker peptide (e.g., polypeptide or protein), marker lipid (e.g., cholesterol), or marker metabolite (e.g., creatinine) such that the presence of the marker is detected in the biological sample.
- an agent for detecting marker mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to marker mRNA or genomic DNA.
- the nucleic acid probe can be, for example, a full-length marker nucleic acid or a portion thereof. Other suitable probes for use in the diagnostic assays of the invention are described herein.
- a compound capable of ameliorating or treating an autoimmune or immune-related disease or condition can include, without limitations, any substance that can improve symptoms or prognosis, prevent progression of the disease or condition, promote regression of the disease or condition, or eliminate the disease or condition.
- this invention provides a method for identifying one or more markers for an autoimmune or immune-related disease or condition comprising: a) determining a first profile of analytes from phagocytic cells from a subject having said disease or condition; determining a second profile of analytes from non-phagocytic cells from the subject having said disease or condition;
- identifying a first set of differences between the first and second profiles wherein the first set of differences is specific to the first profile relative to the second profile; b) determining a third profile of analytes from phagocytic cells from a control subject not having said disease or condition; determining a fourth profile of analytes from non-phagocytic cells from the control subject not having said disease or condition; identifying a second set of differences between the third and fourth profiles, wherein the second set of differences is specific to the third profile relative to the fourth profile; c) identifying one or more analytes specific to the first set of differences relative to the second set of differences, the identified analytes being markers of said disease or condition.
- this method further comprises d) obtaining a fifth profile of analytes from cells or tissues affected by said disease or condition in the subject having said disease or condition; obtaining a sixth profile of analytes from cells or tissues not affected by said disease or condition in the subject having said disease or condition; identifying a third set of differences between the fifth and sixth profiles, wherein the third set of differences is specific to the fifth profile relative to the sixth profile; and e) identifying at least one of the one or more markers of c) present in the third set of differences.
- this invention provides a method for identifying one or more markers of an autoimmune or immune-related disease or condition comprising: a) determining a first profile of analytes from phagocytic cells from a subject having said disease or condition; determining a second profile of analytes from phagocytic cells from a control subject not having said disease or condition; identifying a first set of differences between the first and second profiles, wherein the first set of differences is specific to the first profile relative to the second profile; b) determining a third profile of analytes from non-phagocytic cells from the subject having said disease or condition; determining a fourth profile of analytes from non-phagocytic cells from the control subject not having said disease or condition; identifying a second set of differences between the third and fourth profiles, wherein the second set of differences is specific to the third profile relative to the fourth profile; c) identifying one or more analytes specific to the first set of differences relative to the second set of
- the method further comprises d) obtaining a fifth profile of analytes from cells or tissues affected by said disease or condition in the subject having said disease or condition; obtaining a sixth profile of analytes from cells or tissues not affected by said disease or condition in the subject having said disease or condition; identifying a third set of differences between the fifth and sixth profiles, wherein the third set of differences is specific to the fifth profile relative to the sixth profile; and e) identifying at least one of the one or more markers of c) present in the third set of differences.
- this invention provides a method for identifying one or more markers of an autoimmune or immune-related disease or condition comprising: a) determining a first profile of analytes from phagocytic cells from a subject having said disease or condition; obtaining a second profile of analytes from phagocytic cells from a control subject not having said disease or condition by data mining; identifying a first set of differences between the first and second profiles, wherein the first set of differences is specific to the first profile relative to the second profile; b) determining a third profile of analytes from non-phagocytic cells from the subject having said disease or condition; obtaining a fourth profile of analytes from non-phagocytic cells from a control subject not having said disease or condition by data mining; identifying a second set of differences between the third and fourth profiles, wherein the second set of differences is specific to the third profile relative to the fourth profile; and c) identifying one or more analytes specific to the first set
- the method further comprises d) obtaining a fifth profile of analytes from cells or tissues affected by said disease or condition by data mining; obtaining a sixth profile of analytes from cells or tissues not affected by said disease or condition by data mining; identifying a third set of differences between the fifth and sixth profiles, wherein the third set of differences is specific to the fifth profile relative to the sixth profile; and e) identifying at least one of the one or more markers of c) present in the third set of differences.
- this invention provides a method for identifying one or more markers of an autoimmune or immune-related disease or condition comprising: a) determining a first profile of analytes from phagocytic cells from a subject having said disease or condition; determining a second profile of analytes from non-phagocytic cells from the subject having said disease or condition;
- the method further comprises d) determining a fifth profile of analytes from phagocytic cells from a control subject not having said disease or condition; identifying a third set of differences between the first and fifth profiles, wherein the third set of differences is specific to the first profile relative to the fifth profile; e) identifying at least one of the one or more markers of c) present in the third set of differences.
- the method further comprises: d) obtaining a fifth profile of analytes from cells or tissues affected by said disease or condition from the subject having said disease or condition; obtaining a sixth profile of analytes from cells or tissues not affected by said disease or condition from the subject having said disease or condition;
- An exemplary method for detecting the presence or absence of an analyte e.g., DNA, RNA, protein, polypeptide, carbohydrate, lipid or the like
- an analyte e.g., DNA, RNA, protein, polypeptide, carbohydrate, lipid or the like
- a biological sample e.g., blood
- a bodily fluid sample e.g., blood
- Detection methods described herein can be used to detect one or more markers in a biological sample in vitro as well as in vivo.
- in vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations.
- in vitro techniques for detection of a polypeptide corresponding to a marker of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.
- ELISAs enzyme linked immunosorbent assays
- Western blots Western blots
- immunoprecipitations immunofluorescence
- In vitro techniques for detection of genomic DNA include Southern hybridizations.
- in vivo techniques for detection of a polypeptide corresponding to a marker of the invention include introducing into a subject a labeled antibody directed against the polypeptide.
- the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Because each marker is also an analyte, any method described herein to detect the presence or absence of a marker can also be used to detect the presence or absence of an analyte.
- the marker that is useful in the methods of the invention includes those disclosed in, for example, United States Patents 7,604,948, 7,670,764, 6,986,995, and 6,631,330, United States Patent Application Publication 20070141625, 20090263474, 20100075891, 20100104579, 20100105086, 20100131286, 20090176217, 20090202469, 200201 19118, 20090258025, 20100137393, 20100120629, 20090318392, 20090196927, 20090023166, 20080227709, 20080039402, 20080026378, 20070224638, 20070218519, 20060210562, 20050266432, 20050164233, 20050130245, 20090130683, 20090110667, 20090054321, 20090023166, and 200802741 18, and International Patent
- the marker that is useful in the methods of the invention can also include those markers disclosed in, for example, RM O'Hara, Jr, et al., Drug Discovery Today (2006), 1 1 :342-347; HE Prince, Biomarkers (2005), 10 Suppl 1 :S44-S49; C Selmi and ME Gershwin, Gut (2010), 59:712-713; K Ray, Nature Reviews Rheumatology (2010) 6:380; GP Blaney et al, Ann N Y Acad Sci (2009),
- the marker that is useful in the methods of the invention can include any mutation in any one of the above-identified markers. Mutation sites and sequences can be identified, for example, by databases or repositories of such information, e.g., The Human Gene Mutation Database (www.hgmd.cf.ac.uk), the Single Nucleotide Polymorphism Database (dbSNP,
- the marker that is useful in the methods of the invention can include any marker that is known to be associated with an autoimmune or immune-related disease or condition.
- the present invention also provides kits that comprise marker detection agents that detect at least one or more of the markers identified by the methods of this invention. This present invention also provides methods of treating or preventing an autoimmune or immune-related disease or condition in a subject comprising administering to said subject an agent that modulates the activity or expression of at least one or more of the markers identified by the methods of this invention.
- Example 1 A Representative Method for the Separation of Phagocytic Cells from Non-Phagocytic Cells and the Analysis of Expression Profiles [0138] 1. With reference to FIG. 1C, coat plates with avidin.
- biotinylated antibody to non-phagocytic blood cell (e.g., T cells) to the wells, incubate for 30 min at RT, wash wells.
- non-phagocytic blood cell e.g., T cells
- RNA from phagocytic cells e.g., cells bound to a magnetic bead
- non-phagocytic cells e.g., those cells attached to the bottom of the wells via the anti-non-phagocytic cell biotinylated antibody-avidin bound
- cDNA e.g., whole gene arrays and/or cancer gene arrays
- Isolate protein from each cell sample run Western blots using antibodies to known proteins overexpressed in an individual with an autoimmune or immune-related disease or condition, and compare the profiles obtained in phagocytic and non-phagocytic cells. Alternatively, use mass spectroscopy to identify the proteins.
- Example 2 A Representative Method for the Separation of Phagocytic Cells from Non-Phagocytic Cells and the Analysis of Expression Profiles
- RNA from phagocytic cells and of non-phagocytic cells prepare cDNA, cRNA and use to differentiate genetic profiles (e.g., whole gene arrays and/or disease gene arrays) of phagocytic and non-phagocytic cells.
- Example 3 A Representative Method for the Separation of Phagocytic Cells from Non-Phagocytic Cells and the Analysis of Expression Profiles [0158] 1. With reference to FIG. 1C, lyse RBC from a blood sample.
- [0159] Use magnetic antibody-conjugated beads to isolate non-phagocytic (e.g., T cells) and phagocytic cells (e.g., neutrophils and/or macrophages and/or monocytes) from whole blood.
- non-phagocytic e.g., T cells
- phagocytic cells e.g., neutrophils and/or macrophages and/or monocytes
- RNA from each cell sample prepare cDNA, cRNA and use to differentiate genetic profiles (e.g., cancer gene array) of phagocytic and non- phagocytic cells.
- genetic profiles e.g., cancer gene array
- Example 4 A Representative Method for the Separation of Phagocytic Cells from Non-Phagocytic Cells and the Analysis of Expression Profiles [0164] 1.
- stain WBC with fluorescent antibodies specific against a particular cell subpopulation e.g., neutrophils, macrophages, monocytes, T cells and the like.
- RNA from each cell sample prepare cDNA, cRNA and use to differentiate genetic profiles (e.g., gene array) of phagocytic and non-phagocytic cells.
- Example 5 A Representative Method for the Separation of Phagocytic Cells from Non-Phagocytic Cells and the Analysis of Expression Profiles
- RNA from T cells neutrophils (>2n), macrophages (>2n) , and monocytes (>2n). Then prepare cDNA, cRNA and use to differentiate genetic profiles (e.g., disease gene array) of phagocytic and non-phagocytic cells.
- cDNA, cRNA and use to differentiate genetic profiles (e.g., disease gene array) of phagocytic and non-phagocytic cells.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2806293A CA2806293A1 (en) | 2010-07-23 | 2011-07-22 | Methods of detecting autoimmune or immune-related diseases or conditions |
US13/811,695 US20130184178A1 (en) | 2010-07-23 | 2011-07-22 | Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions |
AU2011280997A AU2011280997A1 (en) | 2010-07-23 | 2011-07-22 | Methods of detecting autoimmune or immune-related diseases or conditions |
EP11810447.0A EP2596116A4 (en) | 2010-07-23 | 2011-07-22 | Methods of detecting autoimmune or immune-related diseases or conditions |
US15/014,476 US11111537B2 (en) | 2010-07-23 | 2016-02-03 | Methods of detecting autoimmune or immune-related diseases or conditions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36701810P | 2010-07-23 | 2010-07-23 | |
US61/367,018 | 2010-07-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/811,695 A-371-Of-International US20130184178A1 (en) | 2010-07-23 | 2011-07-22 | Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions |
US15/014,476 Continuation US11111537B2 (en) | 2010-07-23 | 2016-02-03 | Methods of detecting autoimmune or immune-related diseases or conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012012694A2 true WO2012012694A2 (en) | 2012-01-26 |
WO2012012694A3 WO2012012694A3 (en) | 2012-06-14 |
Family
ID=45497478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/044973 WO2012012694A2 (en) | 2010-07-23 | 2011-07-22 | Methods of detecting autoimmune or immune-related diseases or conditions |
Country Status (5)
Country | Link |
---|---|
US (2) | US20130184178A1 (en) |
EP (1) | EP2596116A4 (en) |
AU (3) | AU2011280997A1 (en) |
CA (1) | CA2806293A1 (en) |
WO (1) | WO2012012694A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040219546A1 (en) * | 2001-04-26 | 2004-11-04 | Shujiro Sakaki | Nonspecific hydridization inhibitors, clinical examination reagents and clinical examination method |
KR101643748B1 (en) * | 2015-08-13 | 2016-07-29 | 충남대학교산학협력단 | Biomarker MicroRNA for Diagnnosis of Tuberculosis |
KR101900539B1 (en) * | 2015-06-19 | 2018-09-20 | 재단법인 아산사회복지재단 | Plasmalogen and ceramide biomarkers for diagnosis of acute transplant rejection in liver transplantation |
US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
US10934588B2 (en) | 2008-01-18 | 2021-03-02 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
US10961578B2 (en) | 2010-07-23 | 2021-03-30 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
US11111537B2 (en) | 2010-07-23 | 2021-09-07 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2666223C1 (en) * | 2017-09-29 | 2018-09-06 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method for predicting the effectiveness of antiretroviral therapy for co-infection with tuberculosis and hiv infection |
CN110221011A (en) * | 2019-05-22 | 2019-09-10 | 南京鼓楼医院 | The fatty acid metabolism object analyzing detecting method of systemic sclerosis diagnosis |
CN110556161B (en) * | 2019-08-13 | 2022-04-05 | 浙江工业大学 | Protein structure prediction method based on conformational diversity sampling |
Family Cites Families (275)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4814434A (en) | 1984-02-03 | 1989-03-21 | Ventres Laboratories, Inc. | Inducer of T-suppressor cells |
US5043267A (en) | 1984-05-18 | 1991-08-27 | E. I. Du Pont De Nemours And Company | Method for rapid detection of bacterial and fungal infection |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
US5077216A (en) | 1988-07-06 | 1991-12-31 | The Trustees Of Dartmouth College | Monoclonal antibodies specific for a human mononculear phagocyte-specific antigen |
US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
DE69326967T2 (en) | 1992-01-17 | 2000-06-15 | Lakowicz Joseph R | Phase modulation energy transfer fluoroimmunoassay |
CA2153387A1 (en) | 1993-01-07 | 1994-07-21 | Hubert Koester | Dna sequencing by mass spectrometry |
WO1994021686A1 (en) | 1993-03-19 | 1994-09-29 | Northern Sydney Area Health Service | Papp-a, its immunodetection and uses |
US5594637A (en) | 1993-05-26 | 1997-01-14 | Base Ten Systems, Inc. | System and method for assessing medical risk |
US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
US5514598A (en) | 1993-11-30 | 1996-05-07 | Doody; Michael | Prenatal detection of meconium |
US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
US6117985A (en) | 1995-06-16 | 2000-09-12 | Stemcell Technologies Inc. | Antibody compositions for preparing enriched cell preparations |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US6031088A (en) | 1996-05-23 | 2000-02-29 | Albert Einstein College Of Medicine Of Yeshiva University | Polycystic kidney disease PKD2 gene and uses thereof |
US20030044859A1 (en) | 1996-08-19 | 2003-03-06 | Henslee Jerry G. | Reagents and methods useful for detecting diseases of the breast |
US20010051341A1 (en) | 1997-03-04 | 2001-12-13 | Isis Innovation Limited | Non-invasive prenatal diagnosis |
GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
JPH11118792A (en) | 1997-10-17 | 1999-04-30 | Ajinomoto Co Inc | Method for sorting macrophage, assay for immunological disease and screening method of remedy for immunological disease |
US20020119118A1 (en) | 1997-11-03 | 2002-08-29 | Genentech, Inc. | Novel polypeptides and nucleic acids encoding bolekine |
JP3301963B2 (en) | 1998-04-14 | 2002-07-15 | 和久 鍬田 | Screening method for severe invasion |
CA2702148C (en) | 1999-01-06 | 2014-03-04 | Genenews Inc. | Method of profiling gene expression in a human subject having an infectious disease |
US6762032B1 (en) | 1999-08-23 | 2004-07-13 | Biocrystal, Ltd. | Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response |
EP1234060A2 (en) * | 1999-11-30 | 2002-08-28 | OXO Chemie AG | Evaluating and predicting clinical outcomes by gene expression analysis |
US20020039736A1 (en) | 2000-06-05 | 2002-04-04 | Byrne Michael C. | Compositions, kits, and methods for identification and modulation of type I diabetes |
ATE375404T1 (en) | 2000-06-27 | 2007-10-15 | Von Recklinghausen Ges E V | METHOD FOR COLLECTING DATA FOR THE PRESYMPTOMATIC OR PRENATAL DIAGNOSIS OF TYPE 1 NEUROFIBROMATOSIS |
US6631330B1 (en) | 2000-08-21 | 2003-10-07 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers |
WO2002028999A2 (en) | 2000-10-03 | 2002-04-11 | Gene Logic, Inc. | Gene expression profiles in granulocytic cells |
US6664056B2 (en) | 2000-10-17 | 2003-12-16 | The Chinese University Of Hong Kong | Non-invasive prenatal monitoring |
WO2002070748A2 (en) | 2000-10-24 | 2002-09-12 | Whitehead Institute For Biomedical Research | Response of dendritic cells to a diverse set of pathogens |
FR2816411B1 (en) | 2000-11-03 | 2003-07-04 | Inst Nat Sante Rech Med | MEANS FOR DETECTING THE PATHOLOGICAL TRANSFORMATION OF THE APP PROTEIN AND THEIR APPLICATIONS |
DK1351707T3 (en) | 2001-01-09 | 2011-07-11 | Baylor Res Inst | Methods for the treatment of autoimmune diseases in an individual and in vitro diagnostic assays |
AU2002245332A1 (en) | 2001-01-29 | 2002-08-12 | The Center For Blood Research, Inc | Anergy-regulated molecules |
US6753137B2 (en) | 2001-01-31 | 2004-06-22 | The Chinese University Of Hong Kong | Circulating epstein-barr virus DNA in the serum of patients with gastric carcinoma |
GB0104690D0 (en) | 2001-02-26 | 2001-04-11 | Cytogenetic Dna Services Ltd | Diagnostic test |
FR2824144B1 (en) | 2001-04-30 | 2004-09-17 | Metagenex S A R L | METHOD OF PRENATAL DIAGNOSIS ON FETAL CELLS ISOLATED FROM MATERNAL BLOOD |
AU2002341488A1 (en) | 2001-05-09 | 2002-11-18 | Biovision Ag | Method for detecting progredient chronic dementia, and associated peptides and detection reagents |
US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
WO2003019193A1 (en) | 2001-08-30 | 2003-03-06 | Ciphergen Biosystems, Inc. | Method of diagnosing nephrotic syndrome |
US6927028B2 (en) | 2001-08-31 | 2005-08-09 | Chinese University Of Hong Kong | Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA |
US20050130245A1 (en) | 2001-09-17 | 2005-06-16 | Syn X Pharma, Inc. | Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins |
US20040038201A1 (en) * | 2002-01-22 | 2004-02-26 | Whitehead Institute For Biomedical Research | Diagnostic and therapeutic applications for biomarkers of infection |
US6986995B2 (en) | 2002-02-28 | 2006-01-17 | Prometheus Laboratories, Inc. | Methods of diagnosing liver fibrosis |
US7744876B2 (en) | 2002-04-09 | 2010-06-29 | The Curators Of The University Of Missouri | Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes |
US7009038B2 (en) | 2002-05-02 | 2006-03-07 | Univ. Of Medicine & Dentistry Of N.J. | pDJA1, a cardiac specific gene, corresponding proteins, and uses thereof |
ES2375181T3 (en) | 2002-05-09 | 2012-02-27 | The Brigham And Women's Hospital, Inc. | 1L 1RL-1 AS A MARKER OF CARDIOVASCULAR DISEASES. |
US20040009518A1 (en) | 2002-05-14 | 2004-01-15 | The Chinese University Of Hong Kong | Methods for evaluating a disease condition by nucleic acid detection and fractionation |
CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US20060094067A1 (en) | 2002-06-26 | 2006-05-04 | Ralf Herwig | Method for the determination of characteristics and/or the classification of circulating macrophages, and analysis arrangement for carrying out said method |
AU2003246380A1 (en) | 2002-07-05 | 2004-01-23 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases |
FR2844279A1 (en) | 2002-09-06 | 2004-03-12 | Inst Nat Sante Rech Med | MEANS FOR DETECTING NEURODEGENERATIVE PROCESSES AND THEIR APPLICATIONS |
US20040141969A1 (en) | 2002-09-16 | 2004-07-22 | Juergen Floege | Method for the treatment of nephritis using anti-PDGF-DD antibodies |
EP1714981A3 (en) | 2002-10-02 | 2006-12-20 | F.Hoffmann-La Roche Ag | Method for the identification of antigenic peptides |
DK1571970T3 (en) | 2002-10-02 | 2011-11-28 | Dmi Biosciences Inc | Diagnosis and monitoring of diseases |
US20040086864A1 (en) | 2002-10-22 | 2004-05-06 | The Chinese University Of Hong Kong | Novel classification methods for pleural effusions |
GB0225360D0 (en) | 2002-10-31 | 2002-12-11 | Univ London | Genetic markers |
US8039218B2 (en) | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
AU2002952993A0 (en) | 2002-11-29 | 2002-12-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Therapeutic and diagnostic agents |
JP4624977B2 (en) | 2003-01-17 | 2011-02-02 | ザ チャイニーズ ユニバーシティ オブ ホンコン | Blood mRNA as a diagnostic marker for pregnancy disorders |
WO2004070388A1 (en) | 2003-02-04 | 2004-08-19 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases |
WO2004071269A2 (en) | 2003-02-13 | 2004-08-26 | Intellectual Property Consulting Inc. | Gene marker and composition for diagnosis and treatment of neurological disorders and diseases and use of the same |
US20040191818A1 (en) | 2003-02-26 | 2004-09-30 | O'toole Margot Mary | Compositions and methods for diagnosing and treating autoimmune diseases |
WO2004079012A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein tyrosine phosphatase-prl-1 a a marker and therapeutic target for pancreatic cancer |
WO2005020784A2 (en) | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
JP4717810B2 (en) | 2003-06-20 | 2011-07-06 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド | Biomarkers for distinguishing between type 1 diabetes and type 2 diabetes |
DE10333406A1 (en) | 2003-07-15 | 2005-02-10 | Protagen Ag | T-regulatory cells containing galectins for the therapy and diagnosis of diseases |
WO2005012907A1 (en) | 2003-08-01 | 2005-02-10 | Renovar, Inc. | Systems and methods for characterizing kidney diseases |
US7323346B2 (en) | 2003-08-14 | 2008-01-29 | The General Hospital Corporation | Screening for gestational disorders |
AU2004270220B2 (en) | 2003-09-05 | 2009-03-05 | The Chinese University Of Hong Kong | Method for non-invasive prenatal diagnosis |
US7445886B2 (en) | 2003-09-10 | 2008-11-04 | Board Of Regents, The University Of Texas System | Macrophage migration inhibitory factor as a marker for cardiovascular risk |
US20050181386A1 (en) | 2003-09-23 | 2005-08-18 | Cornelius Diamond | Diagnostic markers of cardiovascular illness and methods of use thereof |
CA2539535A1 (en) | 2003-10-03 | 2005-04-14 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Use of cripto-1 as a biomarker for neurodegenerative disease and method of inhibiting progression thereof |
CN1930303B (en) | 2003-10-08 | 2013-11-20 | 波士顿大学信托人 | Methods for prenatal diagnosis of chromosomal abnormalities |
EP1524321B2 (en) | 2003-10-16 | 2014-07-23 | Sequenom, Inc. | Non-invasive detection of fetal genetic traits |
US7670764B2 (en) | 2003-10-24 | 2010-03-02 | Prometheus Laboratories Inc. | Methods of diagnosing tissue fibrosis |
US20060094064A1 (en) | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
US20070162983A1 (en) | 2003-11-19 | 2007-07-12 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of the human sgpl1 gene and protein for neurodegenerative diseases |
EP2211183B1 (en) | 2003-11-19 | 2013-03-06 | Satoris, Inc. | Method for diagnosis and monitoring of Alzheimer's disease |
WO2005072340A2 (en) | 2004-01-27 | 2005-08-11 | Compugen Ltd. | Novel polynucleotides encoding polypeptides and methods using same |
US20080269103A1 (en) | 2004-02-04 | 2008-10-30 | Heinz Von Der Kammer | Diagnostic and Therapeutic Use of the Kcne4 Gene and Protein for Alzheimer's Disease |
WO2005082110A2 (en) | 2004-02-26 | 2005-09-09 | Illumina Inc. | Haplotype markers for diagnosing susceptibility to immunological conditions |
DE102004016437A1 (en) * | 2004-04-04 | 2005-10-20 | Oligene Gmbh | Method for detecting signatures in complex gene expression profiles |
DE602005027830D1 (en) | 2004-04-05 | 2011-06-16 | Univ Bordeaux 2 | PEPTIDES AND PEPTIDE MIMETICS BINDING TO CD23 |
US20080051334A1 (en) | 2004-04-16 | 2008-02-28 | Evotec Neurosciences Gmbh | Diagnostic and Therapeutic Use of Kcnc1 for Neurodegenerative Diseases |
US7838245B2 (en) | 2004-04-20 | 2010-11-23 | Sphingotec Gmbh | Use of precursors of tachykinins and/or their fragments in medical diagnostic |
US20090041862A1 (en) | 2004-05-07 | 2009-02-12 | Peter Robert Schofield | Detecting disease association with aberrant glycogen synthase kinase 3beta expression |
US20080038730A1 (en) | 2004-05-10 | 2008-02-14 | Heinz Von Der Kammer | Diagnostic and Therapeutic Use of Kcnj6 for Alzheimer's Disease |
DE602005026931D1 (en) | 2004-05-13 | 2011-04-28 | Brahms Gmbh | USE OF PREPARATIONS OF ENKEPHALINES AND / OR THEIR FRAGMENTS IN MEDICAL DIAGNOSTICS |
WO2005113828A1 (en) | 2004-05-14 | 2005-12-01 | King Pharmaceuticals Research & Development, Inc. | Methods of diagnosing and prognosticating solid tumors and melanoma |
EP2175277B1 (en) | 2004-05-19 | 2013-09-04 | Københavns Universitet | ADAM12 as marker for 2nd trimester Down Syndrome |
US7709194B2 (en) | 2004-06-04 | 2010-05-04 | The Chinese University Of Hong Kong | Marker for prenatal diagnosis and monitoring |
EP1797425A2 (en) | 2004-07-19 | 2007-06-20 | University of Rochester | Biomarkers of neurodegenerative disease |
US20060024757A1 (en) | 2004-07-30 | 2006-02-02 | Robert Hussa | Detection of oncofetal fibronectin for selection of concepti |
WO2006020899A2 (en) | 2004-08-13 | 2006-02-23 | Metrigenix Corporation | Markers for autoimmune disease detection |
WO2006023966A2 (en) | 2004-08-24 | 2006-03-02 | The Trustees Of The University Of Pennsylvania Center For Technology Transfer | Assessment of cardiovascular risk |
US20070087376A1 (en) | 2004-08-30 | 2007-04-19 | Potashkin Judith A | Splice variants of pre-mRNA transcripts as biomarkers in idiopathic neurodegenerative diseases |
WO2006050475A2 (en) | 2004-11-03 | 2006-05-11 | Brigham And Women's Hospital, Inc. | Identification of dysregulated genes in patients with neurological diseases |
WO2006048778A1 (en) | 2004-11-08 | 2006-05-11 | King's College London | Markers of predisposition to addictive states |
US20060115854A1 (en) | 2004-12-01 | 2006-06-01 | Power3 Medical Products, Inc. | Acetyl-LDL receptor related proteins and peptides as a biomarker for neurodegenerative disease |
US20060115855A1 (en) | 2004-12-01 | 2006-06-01 | Power3 Medical Products, Inc. | FK506-binding protein 7 related protein as a biomarker for neurodegenerative disease |
GB0426859D0 (en) | 2004-12-07 | 2005-01-12 | Proteome Sciences Plc | Diagnosis of neurodegenerative disorders |
WO2006061610A2 (en) | 2004-12-07 | 2006-06-15 | Electrophoretics Limited | Diagnosis of neurodegenerative diseases |
JP2008526205A (en) | 2004-12-31 | 2008-07-24 | ジェネンテック・インコーポレーテッド | Polypeptides that bind to BR3 and uses thereof |
FR2880897B1 (en) | 2005-01-18 | 2010-12-17 | Inst Nat Sante Rech Med | METHOD OF DETECTION, NON-INVASIVE, PRENATAL, IN VITRO OF NORMAL HEALTHY CONDITION, HEALTHY CARRIER STATUS OR SICK CARRIER STATUS OF MUCOVISCIDOSIS |
US7432107B2 (en) | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
WO2006083853A2 (en) | 2005-01-31 | 2006-08-10 | Insilicos, Llc | Methods of identification of biomarkers with mass spectrometry techniques |
US7572592B2 (en) | 2005-01-31 | 2009-08-11 | Glycominds Ltd | Method for diagnosing multiple sclerosis |
US20070141625A1 (en) * | 2005-02-03 | 2007-06-21 | Santos Jose H | Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies |
ITRM20050067A1 (en) | 2005-02-17 | 2006-08-18 | Istituto Naz Per Le Malattie I | METHOD FOR THE DETECTION OF VIRAL OR VIRAL NUCLEIC ACIDS IN URINE. |
JP5629051B2 (en) | 2005-03-18 | 2014-11-19 | ザ チャイニーズ ユニバーシティー オブ ホンコンThe Chinese University Of Hongkong | Markers for prenatal diagnosis and monitoring |
JP5219516B2 (en) | 2005-03-18 | 2013-06-26 | ザ チャイニーズ ユニバーシティー オブ ホンコン | Chromosome aneuploidy detection method |
AU2006226891A1 (en) | 2005-03-24 | 2006-09-28 | Beth Israel Deaconess Medical Center | Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy |
ES2346467T3 (en) | 2005-04-06 | 2010-10-15 | Verstappen, Leopold | NEURODEGENERATIVE MARKERS FOR DEPRESSION. |
WO2006111946A2 (en) | 2005-04-18 | 2006-10-26 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Toll-like receptor 14 (tlr14 ) and use thereof |
WO2006114661A1 (en) | 2005-04-26 | 2006-11-02 | Dwek Raymond A | High throughput glycan analysis for diagnosing and monitoring rheumatoid arthritis and other autoimmune diseases |
US7604948B2 (en) | 2005-05-05 | 2009-10-20 | The Regents Of The University Of California | Biomarkers for diagnosing an autism spectrum disorder |
EP2312315A1 (en) | 2005-05-18 | 2011-04-20 | Novartis AG | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component |
US20070015172A1 (en) | 2005-06-01 | 2007-01-18 | Z-Biomed, Inc. | Expression profiles for microbial infection |
WO2006135886A2 (en) | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
GB0512401D0 (en) | 2005-06-17 | 2005-07-27 | Randox Lab Ltd | Method |
GB2428240A (en) | 2005-07-14 | 2007-01-24 | Univ Gen Ve | Diagnostic method for brain damage-related disorders |
US20070148661A1 (en) | 2005-07-19 | 2007-06-28 | Duke University | LSAMP Gene Associated With Cardiovascular Disease |
TW200712493A (en) | 2005-09-28 | 2007-04-01 | Univ Nat Taiwan | Tumor marker for ovarian cancer diagnosis |
US20070218469A1 (en) | 2005-10-03 | 2007-09-20 | Ruth Navon | Novel mutations in hexosaminidase A |
IL172297A (en) | 2005-10-03 | 2016-03-31 | Compugen Ltd | Soluble vegfr-1 variants for diagnosis of preeclamsia |
CN101326439A (en) | 2005-10-11 | 2008-12-17 | 特提斯生物科学公司 | Diabetes-associated markers and methods of use thereof |
WO2007047907A2 (en) | 2005-10-14 | 2007-04-26 | The Regents Of The University Of Michigan | Dek protein compositions and methods of using the same |
AR056786A1 (en) | 2005-11-10 | 2007-10-24 | Smithkline Beecham Corp | COMPOSITE OF 1H- IMIDAZO (4,5-C) PIRIDIN-2-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE TO PREPARE SUCH COMPOSITION, ITS USE TO PREPARE A MEDICATION, USE OF A COMBINATION THAT UNDERTAKES THE COMPOSITE AND AT LEAST AN AGENT TO PREPARE A MEDICINAL PRODUCT AND SUCH COM |
EP1977252B1 (en) | 2005-12-22 | 2012-12-05 | Baxter International Inc. | Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products |
TW200726845A (en) | 2006-01-02 | 2007-07-16 | Nat Defense Medical Ct | Biomarker molecular of renal illness and detecting method for the same |
EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
FR2896588B1 (en) | 2006-01-20 | 2016-08-19 | Univ D'angers | METHOD OF IN VITRO DIAGNOSIS OF AUTOIMMUNE IMMUNE RESPONSE BY DETECTION OF ANTIBODIES AGAINST ANTIGEN PENTRAXIN 3. |
EP1987361A4 (en) | 2006-01-30 | 2009-03-04 | Invitrogen Corp | Compositions and methods for detecting and quantifying toxic substances in disease states |
US7459280B2 (en) | 2006-02-27 | 2008-12-02 | Picobella, Llc | Methods for diagnosing and treating kidney cancer |
NZ570413A (en) | 2006-02-28 | 2011-07-29 | Phenomenome Discoveries Inc | Methods for the diagnosis of dementia and other neurological disorders |
US7488584B2 (en) | 2006-03-24 | 2009-02-10 | Picobella | Methods for diagnosing and treating kidney and colorectal cancer |
US20070224638A1 (en) | 2006-03-27 | 2007-09-27 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
GB0606776D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Pharma Ag | Predictive biomarkers for chronic allograft nephropathy |
EP1847615A1 (en) | 2006-04-18 | 2007-10-24 | Genoscreen | Expression and polymorphism of the ornithine transcarbamylase (OTC) gene as markers for diagnosing Alzheimer's disease |
US7662578B2 (en) | 2006-04-21 | 2010-02-16 | Children's Hospital Medical Center | Method and kit for the early detection of impaired renal status |
ATE517341T1 (en) | 2006-04-27 | 2011-08-15 | Critical Care Diagnostics Inc | INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PREDICTION OF CARDIOVASCULAR DISEASES |
JP5377289B2 (en) | 2006-05-01 | 2013-12-25 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | Diagnostic method for cardiovascular disease |
US7754428B2 (en) | 2006-05-03 | 2010-07-13 | The Chinese University Of Hong Kong | Fetal methylation markers |
US7901884B2 (en) | 2006-05-03 | 2011-03-08 | The Chinese University Of Hong Kong | Markers for prenatal diagnosis and monitoring |
CA2651597C (en) | 2006-05-12 | 2013-02-05 | Keio University | Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease |
WO2007131345A1 (en) | 2006-05-12 | 2007-11-22 | The Hospital For Sick Children | Genetic risk factor in sod1 and sfrs15 in renal disease, diabetic cataract, cardiovascular disease and longevity |
WO2007136679A2 (en) | 2006-05-17 | 2007-11-29 | Ludwig Institute For Cancer Research | Targeting vegf-b regulation of fatty acid transporters to modulate human diseases |
EP2032983A2 (en) | 2006-05-24 | 2009-03-11 | Cellumen, Inc. | Method for modeling a disease |
US20080038269A1 (en) | 2006-05-25 | 2008-02-14 | Mount Sinai Hospital | Methods for detecting and treating kidney disease |
EP2030025A2 (en) | 2006-06-07 | 2009-03-04 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
DE102006027818A1 (en) | 2006-06-16 | 2007-12-20 | B.R.A.H.M.S. Aktiengesellschaft | In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative diseases |
WO2008084331A2 (en) | 2006-06-21 | 2008-07-17 | Hopitaux Universitaires De Geneve | Biomarkers for renal disorders |
WO2008003826A1 (en) | 2006-07-07 | 2008-01-10 | Oy Jurilab Ltd | Novel genes and markers in essential arterial hypertension |
KR100856375B1 (en) | 2006-07-18 | 2008-09-04 | 김현기 | Marker for diagnosing Neurodegenerative diseases |
US7851172B2 (en) | 2006-07-25 | 2010-12-14 | University Of Kentucky Research Foundation | Biomarkers of mild cognitive impairment and alzheimer's disease |
US20080026378A1 (en) | 2006-07-28 | 2008-01-31 | Gian Franco Bottazzo | Prediction and prophylactic treatment of type 1 diabetes |
WO2008014516A2 (en) | 2006-07-28 | 2008-01-31 | Living Microsystems, Inc. | Selection of cells using biomarkers |
ITTO20060614A1 (en) | 2006-08-21 | 2008-02-22 | Uni Degli Studi Del Piemonte | "DIFFERENTIAL DIAGNOSIS FOR THE SCLERODERMIA" |
US20080152589A1 (en) | 2006-09-08 | 2008-06-26 | Peter Schofield | Diagnostics and Therapeutics of Neurological Disease |
US20090318392A1 (en) | 2006-09-14 | 2009-12-24 | Zora Biosciences Oy | Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk |
EP1905841A1 (en) | 2006-09-25 | 2008-04-02 | Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; | Trex1 as a marker for lupus erythematosus |
US20090318354A1 (en) | 2006-09-26 | 2009-12-24 | Proteosys Ag | Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1) |
US8110365B2 (en) | 2006-10-05 | 2012-02-07 | Rhode Island Hospital | Compositions and methods for detecting and treating renal injury and inflammation |
WO2008043725A1 (en) | 2006-10-10 | 2008-04-17 | Novartis Ag | Biomarker in inflammatory disorders |
EP2081649A2 (en) | 2006-10-11 | 2009-07-29 | Novartis AG | Modulation of cd1b or cd1d expression in autoimmune disorders |
US20100081136A1 (en) | 2006-10-16 | 2010-04-01 | Stefan Golz | Crtac as a biomarker, therapeutic and diagnostic target |
WO2008046510A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Fn1 as a biomarker, therapeutic and diagnostic target |
US20100104501A1 (en) | 2006-10-16 | 2010-04-29 | Stefan Golz | Prss23 as a biomarker, therapeutic and diagnostic target |
ES2443042T3 (en) | 2006-10-16 | 2014-02-17 | Bayer Intellectual Property Gmbh | LTBP2 as a biomarker, therapeutic and diagnostic target |
WO2008046160A1 (en) | 2006-10-20 | 2008-04-24 | Newcastle Innovation Limited | Assay for the detection of biomarkers associated with pregnancy related conditions |
US20100159486A1 (en) | 2006-11-01 | 2010-06-24 | George Mason Intellectual Properties, Inc. | Biomarkers for neurological conditions |
JP2010510528A (en) | 2006-11-22 | 2010-04-02 | ライフ テクノロジーズ コーポレーション | Biomarkers for autoimmune diseases |
EP2082237A2 (en) | 2006-12-06 | 2009-07-29 | Universität Zürich | Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same |
IL180095A0 (en) | 2006-12-14 | 2007-05-15 | Ohad Birk | Method for antenatal estimation of down syndrome risk |
US20090104605A1 (en) * | 2006-12-14 | 2009-04-23 | Gary Siuzdak | Diagnosis of sepsis |
US8362224B2 (en) | 2006-12-19 | 2013-01-29 | The Trustees Of The University Of Pennsylvania | Screening for CD93 (C1qRp)-associated polymorphism(S) in the diagnosis, prevention and treatment of autoimmune diseases |
US8815519B2 (en) | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
EP2155228B1 (en) | 2007-01-10 | 2014-04-02 | Purdue Research Foundation | Polypeptide inhibitors of hsp27 kinase and uses therefor |
WO2008085024A1 (en) | 2007-01-12 | 2008-07-17 | Erasmus University Medical Center Rotterdam | Identification and detection of peptides relating to specific disorders |
WO2008089936A1 (en) | 2007-01-22 | 2008-07-31 | Medizinische Universität Innsbruck | Novel markers for chronic kidney disease |
EP2115167A1 (en) | 2007-02-08 | 2009-11-11 | Powmri Limited | Method of diagnosing a neurodegenerative disease |
WO2008100596A2 (en) | 2007-02-15 | 2008-08-21 | Burnham Institute For Medical Research | Biomarkers of neurodegenerative disease |
MX2009008878A (en) | 2007-02-21 | 2009-08-28 | Decode Genetics Ehf | Genetic susceptibility variants associated with cardiovascular disease. |
WO2008112772A2 (en) | 2007-03-14 | 2008-09-18 | Baylor Research Institute | Gene expression in peripheral blood mononuclear cells from children with diabetes |
WO2008118813A2 (en) | 2007-03-26 | 2008-10-02 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Schizophrenia-related isoform of kcnh2 and development of antipsychotic drugs |
EP1975252A1 (en) | 2007-03-29 | 2008-10-01 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Methods for the prognosis or for the diagnosis of a thyroid disease |
WO2008120684A1 (en) | 2007-03-30 | 2008-10-09 | Yamaguchi University | Method for determining prognosis of acute central nervous system disorder |
EP2579038B1 (en) | 2007-04-12 | 2014-10-01 | Universiteit Hasselt | Biomarkers for multiple sclerosis |
GB0707933D0 (en) | 2007-04-24 | 2007-05-30 | Apitope Technology Bristol Ltd | Disease markers |
GB0708075D0 (en) | 2007-04-26 | 2007-06-06 | Univ Nottingham | Nethods |
AU2008247649A1 (en) | 2007-05-01 | 2008-11-13 | University Of Miami | Transcriptomic biomarkers for individual risk assessment in new onset heart failure |
EP2076590A4 (en) | 2007-05-03 | 2011-06-01 | Medimmune Llc | Auto-antibody markers of autoimmune disease |
WO2008147938A2 (en) | 2007-05-24 | 2008-12-04 | Centocor, Inc. | Wnt5a as an inflammatory disease marker |
WO2008154238A1 (en) | 2007-06-06 | 2008-12-18 | Siemens Healthcare Diagnostics Inc. | Predictive diagnostics for kidney disease |
EP2164983A1 (en) | 2007-06-08 | 2010-03-24 | Vib Vzw | The novel adipocytokine visfatin/pbef1 is an apoptosis associated factor induced in monocytes during in vivo hiv-1 infection |
EP2158326B1 (en) | 2007-06-21 | 2012-06-20 | The Board of Trustees of The Leland Stanford Junior University | Biomarkers for rheumatoid arthritis |
ITRM20070351A1 (en) | 2007-06-22 | 2008-12-23 | Istituto Naz Per Le Malattie I | GENE CODIFYING AMBER PROTEIN 1 HAVING REGULATORY ACTIVITY OF THE SELF-FAILURE AND DEVELOPMENT OF THE CENTRAL NERVOUS SYSTEM |
WO2009000520A1 (en) | 2007-06-25 | 2008-12-31 | Universität Duisburg-Essen | Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders |
WO2009003142A1 (en) | 2007-06-27 | 2008-12-31 | The Board Of Trustees Of The Leland, Stanford Junior University | Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease |
JP2010533866A (en) | 2007-07-13 | 2010-10-28 | ジェネンテック, インコーポレイテッド | Methods for treating and diagnosing cancer, inflammatory diseases and autoimmune diseases |
ES2443540T3 (en) | 2007-07-17 | 2014-02-19 | Metabolon, Inc. | Biomarkers for pre-diabetes and methods that use them |
US20110081649A1 (en) | 2007-08-02 | 2011-04-07 | Iss Immune System Stimulation Ab | Diagnosis, staging and monitoring of inflammatory bowel disease |
WO2009032722A1 (en) | 2007-08-29 | 2009-03-12 | The Cleveland Clinic Foundation | Carbamylated proteins and risk of cardiovascular disease |
US20090275046A1 (en) | 2007-08-29 | 2009-11-05 | Power3 Medical Products, Inc. | Complement factor H protein as a biomarker of Parkinson's disease |
US8748100B2 (en) | 2007-08-30 | 2014-06-10 | The Chinese University Of Hong Kong | Methods and kits for selectively amplifying, detecting or quantifying target DNA with specific end sequences |
GB0717637D0 (en) | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
US8062852B2 (en) * | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
ITUD20070183A1 (en) | 2007-10-01 | 2009-04-02 | Univ Degli Studi Udine | DIAGNOSTIC AND PROGNOSTIC METHOD FOR DIAGNOSIS AND PROGNOSIS OF LYMPHOPROLIFERATION IN AUTOIMMUNE DISEASES |
EP2209810A1 (en) | 2007-10-15 | 2010-07-28 | King's College London | Viral therapeutic |
EP2212693B1 (en) | 2007-10-22 | 2015-04-22 | The Regents of The University of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
FI20070795A0 (en) | 2007-10-24 | 2007-10-24 | Faron Pharmaceuticals Oy | A new biomarker for monitoring disease development and assessing the effectiveness of therapies |
JP2011501177A (en) | 2007-10-26 | 2011-01-06 | ビオヒット・ユルキネン・オサケユキテュア | Methods and products for diagnosing gastric cancer associated with autoimmune disease and atrophic gastritis |
WO2009059259A2 (en) | 2007-10-31 | 2009-05-07 | Children's Hospital Medical Center | Detection of worsening renal disease in subjects with systemic lupus erythematosus |
WO2009058168A1 (en) | 2007-11-04 | 2009-05-07 | Prediction Sciences Llc | Cellular fibronectin as a diagnostic marker in cardiovascular disease and methods of use thereof |
US20100233716A1 (en) | 2007-11-08 | 2010-09-16 | Pierre Saint-Mezard | Transplant rejection markers |
WO2009065132A1 (en) | 2007-11-16 | 2009-05-22 | Oklahoma Medical Research Foundation | Predicting and diagnosing patients with autoimmune disease |
EP2245188A2 (en) | 2007-11-28 | 2010-11-03 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Biomarkers for the onset of neurodegenerative diseases |
US8506933B2 (en) | 2007-11-30 | 2013-08-13 | Msdx, Inc. | Methods of detecting a neurological condition via analysis of circulating phagocytes |
WO2009074331A2 (en) | 2007-12-11 | 2009-06-18 | Julius-Maximilians-Universität Würzburg | Early and differential diagnosis test for alzheimer's disease |
WO2009075566A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
EP2075343A1 (en) | 2007-12-21 | 2009-07-01 | Gert Mayer | A method of diagnosing a progressive disease |
EP2240601B1 (en) | 2007-12-27 | 2016-10-12 | Compugen Ltd. | Biomarkers for the prediction of renal injury |
EP3358354B1 (en) * | 2008-01-18 | 2020-07-15 | President and Fellows of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
NZ586746A (en) | 2008-01-23 | 2012-07-27 | Righospitalet | Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40 |
US20090299155A1 (en) | 2008-01-30 | 2009-12-03 | Dexcom, Inc. | Continuous cardiac marker sensor system |
JP2011511301A (en) | 2008-02-04 | 2011-04-07 | バンヤン・バイオマーカーズ・インコーポレイテッド | Methods for diagnosing or treating brain injury |
CA2714410A1 (en) | 2008-02-08 | 2009-08-13 | Medimmune, Llc | Disease markers and uses thereof |
US20090239242A1 (en) | 2008-03-18 | 2009-09-24 | Biotrin Intellectual Properties Limited | Method for the early identification and prediction of kidney injury |
CA2646040A1 (en) | 2008-03-22 | 2009-09-22 | David V. Pow | Detection of a biomarker of aberrant cells of neuroectodermal origin in a body fluid |
GB0809069D0 (en) | 2008-05-19 | 2008-06-25 | Univ Leuven Kath | Gene signatures |
EP2107377A1 (en) | 2008-04-04 | 2009-10-07 | BRAHMS Aktiengesellschaft | Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events |
WO2009122387A1 (en) | 2008-04-04 | 2009-10-08 | Biotrin Group Ltd. | Method for the detection and prediction of obesity-related renal disease |
CA2720644A1 (en) | 2008-04-15 | 2009-10-22 | Rainer Oberbauer | Markers of acute kidney failure |
US8030097B2 (en) | 2008-04-30 | 2011-10-04 | Versitech Limited and R & C Biogenius Limited | Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks |
WO2010005750A2 (en) | 2008-06-16 | 2010-01-14 | The Regents Of The University Of California | Potential prognostic markers and therapeutic targets for neurological disorders |
US20100167937A1 (en) | 2008-07-08 | 2010-07-01 | Power3 Medical Products, Inc. | Multiple forms of Alzheimer's disease based on differences in concentrations of protein biomarkers in blood serum |
ES2532153T3 (en) | 2008-07-18 | 2015-03-24 | Trovagene, Inc. | Methods for detecting "ultrashort" nucleic acid sequences based on PCR |
WO2010011506A2 (en) | 2008-07-23 | 2010-01-28 | The Washington University | Risk factors and a therapeutic target for neurodegenerative disorders |
US8859725B2 (en) | 2008-07-31 | 2014-10-14 | Queen Mary And Westfield College, University Of London | Healthy kidney biomarkers |
NO2324360T3 (en) | 2008-08-11 | 2018-06-30 | ||
ES2341419B1 (en) | 2008-08-14 | 2011-05-03 | Hospital Clinic I Provincial De Barcelona | WNT1 AS RENAL DAMAGE BIOMARCATOR. |
US8673574B2 (en) | 2008-08-21 | 2014-03-18 | Pxbiosciences Llc | Diagnosis and monitoring of renal failure using peptide biomarkers |
CN105021826A (en) | 2008-08-29 | 2015-11-04 | 阿斯图特医药公司 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
EP2161577A1 (en) | 2008-09-01 | 2010-03-10 | Atlas Antibodies AB | ANLN protein |
WO2010039714A1 (en) | 2008-09-30 | 2010-04-08 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists |
US20100124756A1 (en) | 2008-10-10 | 2010-05-20 | Sandip Ray | Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids |
GB0818650D0 (en) | 2008-10-10 | 2008-11-19 | Uni I Oslo | Methods |
CN106370857A (en) | 2008-10-21 | 2017-02-01 | 阿斯图特医药公司 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
CN104076152B (en) | 2008-10-21 | 2017-04-19 | 阿斯图特医药公司 | Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure |
KR101051435B1 (en) | 2008-10-22 | 2011-07-22 | 한국생명공학연구원 | Colorectal cancer diagnostic kit using colorectal cancer-related markers and colorectal cancer diagnostic method using the same |
EP2180322A1 (en) | 2008-10-22 | 2010-04-28 | BRAHMS Aktiengesellschaft | Prognostic biomarkers for the progression of primary chronic kidney disease |
WO2010048497A1 (en) | 2008-10-24 | 2010-04-29 | Genizon Biosciences Inc. | Genetic profile of the markers associated with alzheimer's disease |
CA2741114A1 (en) | 2008-10-24 | 2010-04-29 | Cornelis Lammert Verweij | Biomarkers for predicting the development of chronic autoimmune diseases |
WO2010054167A2 (en) | 2008-11-06 | 2010-05-14 | University Of Miami | Limited proteolysis of cd2ap and progression of renal disease |
SG195652A1 (en) | 2008-11-07 | 2013-12-30 | Sequenta Inc | Methods of monitoring conditions by sequence analysis |
NZ592488A (en) | 2008-11-10 | 2012-10-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US20100120050A1 (en) | 2008-11-11 | 2010-05-13 | Entelos, Inc. | Biomarkers For Assessing Altherosclerotic Potential |
WO2010059242A2 (en) | 2008-11-21 | 2010-05-27 | The Johns Hopkins University | Neurodegenerative disease diagnostic compositions and methods of use |
AU2009316387B2 (en) | 2008-11-22 | 2015-01-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
IT1392551B1 (en) | 2008-11-25 | 2012-03-09 | Bioindustry Park Del Canavese S P A | BIOMARCERS FOR DIAGNOSIS AND TO DETECT THE PROGRESSION OF NEURODEGENERATIVE DISEASES, IN PARTICULAR OF AMIOTROPHIC LATERAL SCLEROSIS |
NZ628281A (en) | 2008-12-09 | 2016-05-27 | Stephanie Fryar Williams | Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders |
ES2706403T3 (en) | 2008-12-10 | 2019-03-28 | Joslin Diabetes Center Inc | Methods to diagnose and predict kidney disease |
EP2596353A4 (en) | 2010-07-23 | 2014-01-15 | Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
US20130210647A1 (en) | 2010-07-23 | 2013-08-15 | President And Fellows Of Harvard College | Methods of Detecting Cardiovascular Diseases or Conditions |
BR112013001754A2 (en) | 2010-07-23 | 2016-05-31 | Harvard College | method for detecting disease marks or conditions in body fluids |
EP2596133A4 (en) | 2010-07-23 | 2014-04-23 | Harvard College | Methods of detecting neurological or neuropsychiatric diseases or conditions |
WO2012012704A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting kidney-associated diseases or conditions |
BR112013001752A2 (en) | 2010-07-23 | 2016-05-31 | Harvard College | method of detecting disease or condition using phagocytic cells |
WO2012012694A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
US20140141986A1 (en) | 2011-02-22 | 2014-05-22 | David Spetzler | Circulating biomarkers |
-
2011
- 2011-07-22 WO PCT/US2011/044973 patent/WO2012012694A2/en active Application Filing
- 2011-07-22 CA CA2806293A patent/CA2806293A1/en not_active Abandoned
- 2011-07-22 AU AU2011280997A patent/AU2011280997A1/en not_active Abandoned
- 2011-07-22 US US13/811,695 patent/US20130184178A1/en not_active Abandoned
- 2011-07-22 EP EP11810447.0A patent/EP2596116A4/en not_active Withdrawn
-
2016
- 2016-02-03 US US15/014,476 patent/US11111537B2/en active Active
- 2016-05-09 AU AU2016202956A patent/AU2016202956A1/en not_active Abandoned
-
2018
- 2018-05-08 AU AU2018203197A patent/AU2018203197A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of EP2596116A4 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8252531B2 (en) * | 2001-04-26 | 2012-08-28 | Nof Corporation | Nonspecific hybridization inhibitors, clinical examination reagents and clinical examination method |
US20040219546A1 (en) * | 2001-04-26 | 2004-11-04 | Shujiro Sakaki | Nonspecific hydridization inhibitors, clinical examination reagents and clinical examination method |
US11001894B2 (en) | 2008-01-18 | 2021-05-11 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
US10934588B2 (en) | 2008-01-18 | 2021-03-02 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
US10934589B2 (en) | 2008-01-18 | 2021-03-02 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
US10961578B2 (en) | 2010-07-23 | 2021-03-30 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
US11111537B2 (en) | 2010-07-23 | 2021-09-07 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
KR101900539B1 (en) * | 2015-06-19 | 2018-09-20 | 재단법인 아산사회복지재단 | Plasmalogen and ceramide biomarkers for diagnosis of acute transplant rejection in liver transplantation |
WO2017026606A1 (en) * | 2015-08-13 | 2017-02-16 | 충남대학교산학협력단 | Biomarker microrna for diagnosing tuberculosis |
KR101643748B1 (en) * | 2015-08-13 | 2016-07-29 | 충남대학교산학협력단 | Biomarker MicroRNA for Diagnnosis of Tuberculosis |
Also Published As
Publication number | Publication date |
---|---|
EP2596116A4 (en) | 2014-03-19 |
US11111537B2 (en) | 2021-09-07 |
WO2012012694A3 (en) | 2012-06-14 |
AU2018203197A1 (en) | 2018-05-31 |
US20160153984A1 (en) | 2016-06-02 |
EP2596116A2 (en) | 2013-05-29 |
AU2016202956A1 (en) | 2016-05-26 |
AU2011280997A1 (en) | 2013-02-28 |
US20130184178A1 (en) | 2013-07-18 |
CA2806293A1 (en) | 2012-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11111537B2 (en) | Methods of detecting autoimmune or immune-related diseases or conditions | |
EP2596117B1 (en) | Methods of detecting kidney-associated diseases or conditions | |
US20170268061A1 (en) | Methods of Detecting Diseases or Conditions Using Phagocytic Cells | |
US20160160284A1 (en) | Methods of Detecting Neurological or Neuropsychiatric Diseases or Conditions | |
US10961578B2 (en) | Methods of detecting prenatal or pregnancy-related diseases or conditions | |
EP2596349B1 (en) | Methods of detecting cardiovascular diseases or conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11810447 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2806293 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011810447 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011280997 Country of ref document: AU Date of ref document: 20110722 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13811695 Country of ref document: US |